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Modafinil is an FDA-approved drug for the treatment of narcolepsy with
efficacy in the treatment of chronic fatigue syndrome, obstructive sleep apnea,
and shift-work sleep disorder. Modafinil’s wake-promoting and cognitiveenhancing effects are reportedly similar to those of traditional psychostimulants,
but without the side effects typically associated with these substances. Modafinil
has also been investigated as an agonist replacement therapy for
psychostimulant dependence, although results of clinical trials are equivocal.
Few studies have examined its behavioral effects in combination with
psychostimulants and the neuropharmacological actions of modafinil are not well
understood. The primary aim of this study was to assess modafinil’s effects in
combination with the psychomotor stimulant, d-amphetamine, in four experiments
utilizing preclinical behavioral assays of abuse liability. A secondary aim was to
investigate modafinil’s neuropharmacological actions utilizing drug discrimination,
an in vivo preclinical screening procedure with established predictive validity.
The first experiment utilized a behavioral sensitization assay to determine if
repeated d-amphetamine treatment followed by a washout period would produce
cross sensitization to modafinil. Experiment 2 utilized a conditioned place

preference (CPP) assay to determine if modafinil would establish a CPP or
influence d-amphetamine-induced CPP. Experiment 3 utilized a drug
discrimination assay to evaluate generalization with modafinil alone and with
d-amphetamine in rats trained to discriminate d-amphetamine. Experiment 4
assessed several dopaminergic compounds for substitution or antagonism in rats
trained to discriminate 256 mg/kg modafinil. Experiment 1 results indicated that
repeated d-amphetamine treatment does not induce cross sensitization to
modafinil. Experiment 2 results demonstrated that modafinil does not readily
establish CPP or potentiate d-amphetamine-induced CPP. Modafinil produced
dose-dependent d-amphetamine-lever responses and partial substitution for
d-amphetamine in Experiment 3. Experiment 4 results represent the first
demonstration that modafinil’s actions at the dopamine transporter are important
in maintaining its discriminative stimulus effects. Considered together, these
findings support previous reports of modafinil’s low abuse potential, but also
indicate that it may have additive effects with psychomotor stimulants. In
consideration of modafinil as a potential candidate for agonist replacement
therapy, further preclinical investigations of modafinil in combination with other
stimulants, such as drug self-administration, may be warranted.
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CHAPTER I
INTRODUCTION
General Overview
Modafinil is a wake-promoting drug manufactured by Cephalon with FDA
approval for the treatment of narcolepsy and is reportedly effective in the
treatment of chronic fatigue syndrome (Turkington, Hedwat, Rider, & Young,
2004), obstructive sleep apnoea/hypopnoea syndrome, and shift work sleep
disorder (Keating & Raffin, 2005). In addition to being prescribed for these FDAapproved disorders, it has also been investigated to treat fatigue in patients with
Parkinson’s disease (Hogl, Saletu, Brandauer, Glatzi, Frauscher, Seppi, Ulmer,
Wenning, & Poewe, 2002), amyotrophic lateral sclerosis (Carter, Weiss, Lou,
Jensen, Abresch, Martin, Hecht, Han, Weydt, & Kraft, 2005), fibromyalgia
(Pachas, 2003), cancer (Blackhell, Petroni, Su, Baum, & Farace, 2009), multiple
sclerosis (Volkmer, Heesen, & Liepert, 2009), and dementia (Howcroft & Jones,
2005) in addition to attention deficit hyperactivity disorder (Taylor & Russo,
2000). Modafinil’s wake-promoting (Hermant, Rambert, & Duteil, 1991; Silvestri,
Sanford, Ross, Mann, Pavlock, & Morrison, 2002; Webb, Pollock, & Mistlberger,
2006) and cognitive-enhancing effects (Turner, Robbins, Clark, Aron, Dowson, &
Sahakian, 2003) are similar to those of traditional psychostimulants, apparently
without the side effects (e.g., tolerance, abuse potential, sleep rebound, and
increased locomotor activity or hyperactivity) typically associated with these
substances (Deroche-Gamonet, Darnaudery, Bruins-Slot, Piat, & Piazza, 2002;
Hermant et al., 1991; Lin, Roussel, Akaoka, Fort, Debilly, & Jouvet, 1992). The
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following literature review addresses the current state of knowledge regarding the
cognitive effects, abuse liability, and neurochemical actions of modafinil based on
human and nonhuman research investigations.

Cognitive Enhancing Effects of Modafinil
Human Populations
Human clinical investigations of the cognitive and performance-enhancing
properties of modafinil have mainly involved assessments in sleep-deprived
individuals or in populations with neurological disorders. Improved response time
on vigilance tasks (Wesensten, Killgore, & Balking, 2005) and executive function
measures (Walsh, Randazzo, Stone, & Schweizer, 2004; Baranski, Gill,
McLellan, Moroz, Buguet, & Radomski, 2002) were enhanced by modafinil
administration in sleep-deprived individuals. Other studies utilizing sleepdeprived individuals have found improved performance and alertness in aviators
in a simulated helicopter flight (Caldwell, Caldwell, Smythe, & Hall, 2000). In
fact, modafinil attenuated the decline in simulated flight performance (Dagan &
Doljansky, 2006), and improved attentional focus, response selection, and
reduced impulsivity (Gill, Haerich, Westcott, Godenick, & Tucker, 2006) in this
population.
Studies of individuals with schizophrenia or ADHD also show
enhancement of cognitive abilities following modafinil administration. Modafinil
administration in adults with ADHD led to improved scores on short-term memory
span (the Digit Span Task), visual memory (Pattern Recognition Memory and
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Delayed Matching to Sample Tasks), spatial planning (Tower of London Task),
decision-making (Gamble Task), and sustained attention in the Rapid Visual
Information Processing (RVIP) Task (Turner, Clark, Dowson, Robbins, &
Sahakian, 2004a). In patients with schizophrenia, modafinil resulted in cognitive
improvements in the Digit Span Task and an intra-dimensional/extra-dimensional
task (IDED), which is a three-dimensional version of a set-shifting task measuring
selective attention (Turner, Clark, Pomarol-Clotet, McKenna, Robbins, &
Sahakian, 2004b). Few studies have demonstrated modafinil-induced cognitive
benefits in patients with other conditions associated with cognitive decline,
although one study in participants with narcolepsy described a decreased
number of errors from baseline seen on the Wisconsin Card Sorting Task
(Schwartz, Nelson, Schwartz, & Hughes, 2004). In addition, a recent study of
seven methamphetamine-dependent participants seeking treatment documented
significant increases in verbal memory recall and trends toward improvements in
other executive functions (Hester, Lee, Pennay, Nielsen, & Ferris, 2010).
Despite considerable evidence that modafinil produces cognitive benefit
in some neurological populations, results of research involving non sleepdeprived, healthy individuals are equivocal. Randall and colleagues reported that
modafinil does not act as a cognitive-enhancer in young (n = 30) or middle-aged
individuals who are not sleep-deprived (Randall, Shneerson & File, 2004;
Randall, Shneerson, Plaha & File, 2003). However, a later study by the same
investigators involving more young participants (n = 60) found that modafinil
enhanced the speed of response time in the color naming task of the Stroop test,
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and improvements in the Digit Span task (a measure of working memory), the
Pattern Recognition Memory (PRM) tests, and the RVIP in the healthy young
adult sample (Randall, Viswanath, Bharania, Elsabagh, Hartley, Shneerson, &
File, 2005; Turner et al., 2003). Specifically, improvements in verbal recall were
found in the Digit Span Task and the modafinil group recognized more patterns in
the PRM tests.
In addition to enhancements in working memory and performance on
spatial tasks, modafinil appears to have an effect on attention and impulsivity
measures. A study in healthy individuals found modafinil decreased the number
of omission errors in the RVIP Task after administration of 200 mg/kg modafinil
(Randall et al., 2005) and after approximately 300 mg/kg in the Detection of
Repeated Numbers (DRN) Task (Baranski, Pigeau, Dinich, & Jacobs, 2004),
both measures of sustained attention. Increased accuracy in attentional setshifting has also been reported (Marchant, Kamel, Echlin, Grice, & Lewis, 2009),
but only at the most difficult levels of the task. Reduced impulsivity or increased
inhibition has also been demonstrated in humans using the stop-signal task
(STOP) (Turner et al., 2003).
In sum, paradigms utilizing working memory tasks have shown decreased
errors after modafinil administration that were not dependent on task difficulty,
but rather on baseline performance (Muller, Steffenhagen, Regenthal, & Bublak,
2004). Those individuals who had poorer baseline scores were those who
benefited the most from modafinil use. Modafinil, therefore, may improve
cognitive performance in young, healthy individuals on specific types of cognitive
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tasks, such as working memory and spatial tasks. However, evidence for
improvements in impulsivity, attentional measures, and decision making tasks
are equivocal and may be more specific to task difficulty or those individuals with
preexisting cognitive deficits, such as would exist in sleep-deprived or aged
individuals, or individuals with ADHD, schizophrenia, or other cognitive
impairments.
Nonhuman Animal Populations
A number of animal studies investigating modafinil have also
demonstrated cognitive improvements in non sleep-deprived, healthy, young
rats. Specifically, improvements have been found in learning and working
memory tasks, consistent with the human literature (Randall et al., 2005; Turner
et al., 2003). Modafinil-treated rats learned the win-stay rule in a Serial Spatial
Discrimination Reversal (SSDR) Task (Beracochea, Celerier, Peres, & Pierard,
2003; Beracochea, Celerier, Borde, Valleau, Peres, & Pierard, 2002) and in a
Delayed Nonmatching to Position Swim Task (Ward, Harsh, York, Stewart, &
McCoy, 2004) in fewer trials than controls. Acquisition of the Morris water maze
task, a measure of spatial memory, was enhanced in a group of mice that
received 75 mg/kg modafinil during training, although an acute injection of the
same dose did not enhance performance in animals with no drug pretreatment
(Shuman, Cai, Sage, & Anagnostaras, 2012). Assessment of modafinil
pretreatment on learning in a Pavolovian fear conditioning paradigm revealed
significant differences from saline-treated animals in task acquisition and percent
of time spent freezing (Shuman, Wood, & Anagnostaras, 2009). In a study
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examining the cognitive enhancing effects of modafinil in an animal model of
pharmacologically-induced impairment with phencyclidine (PCP), modafinil
attenuated effects in the extradimensional set shift task of the preclinical ID-ED
task, the cognitive function most impaired by PCP administration (Goetghebeur &
Dias, 2009).
Assessments of attention and impulsivity measures have also found
promising, though equivocal, performance-enhancing results after modafinil
administration in young, non-impaired rats. In a Five-Choice Serial Reaction
Time Task (5-CSRTT), modafinil administration decreased the number of
omission errors, indicating an increased level of sustained attention, but
increased the number of premature responses, suggesting a lack of inhibition or
increased impulsivity (Milstein, Dalley, Theobold, & Robbins, 2003). Other
research utilizing the same paradigm found discrepant results and reported no
improvement in sustained, selective, or divided attention after modafinil
administration (Waters, Burnham, O’Connor, Dawson, & Dias, 2005).
Furthermore, research utilizing a modified version of the 5-CSRTT with only three
operanda (3-CSRTT) found no effects on sustained or selective attention in
young, healthy adult rats after modafinil administration (Colclasure, Campbell,
Quisenberry, Miller, Dopheide, & Morgan, 2006), although another study utilizing
this apparatus did find increased premature responses after modafinil (64 mg/kg)
administration in young Long-Evans rats (Quisenberry, 2007). It should be noted
that the age of the animals was not reported in the Milstein et al. (2003) or the
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Waters et al. (2005) studies and age may very well influence the cognitive
enhancing effects of modafinil.
Similar to the findings of modafinil-induced enhancement in cognitivelyimpaired clinical populations, a study of middle-aged animals found evidence of
modafinil-induced facilitation of attention (Morgan, Crowley, Smith, LaRoche, &
Dopheide, 2007). Specifically, improvements in impulse control were seen, as
measured by a reduction in the percentage of premature responses, as well as
improved response accuracy and reaction time following oral administration of 64
mg/kg modafinil, but not with lower doses. A similar study validated the results of
the attention measures and reported increased sustained attention, measured by
an increase in percent accurate trails, but reported no effect on premature
responses or impulsivity in aged Long-Evans rats (Quisenberry, 2007).
Cognitive improvements associated with modafinil use may contribute to
its potential for abuse in some populations. However, the clinical and preclinical
research literature indicate that modafinil’s abuse liability is fairly low. This
literature is reviewed in the next section.

Abuse Liability Assessments and Therapeutic Implications for Modafinil in
Substance Abuse/Dependence
Basic Human Studies on Subjective Effects
Several double blind, placebo controlled studies have evaluated the
subject-rated effects of modafinil in healthy adults with or without substance
abuse histories. For example, in a sample of 16 healthy adults without a
substance abuse history, the Profile of Mood States, Addiction Research Center
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Inventory, and a Visual Analog scale were utilized to compare subject-rated and
behavioral effects of a single oral dose of 300 mg modafinil and 15 mg
dextroamphetamine at 1, 2, 4 and 8 hour post-dose intervals (Warot, Corruble,
Payan, Weil, & Puech, 1993). The authors reported that modafinil ratings were
markedly different from those of d-amphetamine and more similar to caffeine
ratings. In contrast, in a more recent study evaluating a wider range of doses in
12 healthy adults without a substance abuse history, modafinil and amphetamine
were reported to produce qualitatively and quantitatively similar effects (Makris,
Rush, Frederich, Taylor, & Kelly, 2007).
Other human laboratory studies of modafinil’s psychoactive effects
indicate that oral modafinil administration at clinically effective doses does not
appear to have strong reinforcing properties, and may produce different subjectrated effects in participants with and without a history of psychostimulant use
(Malcolm, Swayngim, Donovan, DeVane, Elkashef, Chiang, Khan, Mojsiak,
Myrick, Hedden, Cochran & Woolson, 2006; Rush, Kelly, Hays, Baker, &
Wooten, 2002; Warot et al., 1993). Participants with a history of stimulant use
reported different ratings on measures of drug-liking, mood, anxiety, and fatigue
between modafinil and amphetamine (Malcolm et al., 2006). On the contrary,
humans without a history of psychostimulant use appear to be more likely to
characterize the effects of modafinil as amphetamine-like (Mackris et al., 2007;
Stoops, Lile, Fillmore, Glaser, & Rush, 2005). Only one study has investigated
the abuse liability of modafinil in a human choice self-administration paradigm.
The results of this study support results obtained from subject-rated effects in
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psychostimulant users. Twelve cocaine abusers not seeking treatment did not
choose modafinil more frequently than placebo (Vosburg, Hart, Haney, Rubin &
Foltin, 2010).
Findings are generally consistent that participants with a history of
psychostimulant abuse can readily distinguish the effects of modafinil from either
cocaine or amphetamine (Malcolm et al., 2006; Rush et al., 2002). However,
evidence that psychostimulant users can discriminate the effects of modafinil
from those of other psychostimulants does not necessarily preclude the
possibility that modafinil could be established as a therapeutic agent to assist in
recovery from psychostimulant abuse and/or dependence.
Modafinil as a Treatment for Dependence
Modafinil has been evaluated as a potential treatment for amphetamine
(Mann & Bitsios, 2008), methamphetamine (Shearer, Darke, Rodgers, Slade, van
Beek, Lewis, Brady, McKetin, Mattick, & Wodak, 2009), and cocaine (Dackis,
Kampman, Lynch, Pettinati, & O’Brien, 2005) dependence and abuse in clinical
populations. Many factors make modafinil a promising candidate for this type of
pharmacotherapy. Notably, no major side effects have been reported, no deaths
have occurred, and any effect of modafinil overdose was mild (Carstairs,
Urquhart, Hoffman, Clark, & Cantrell, 2010). Abuse liability assessments in
animals (Deroche-Gamonet et al., 2002) and humans (Vosburg et al., 2010)
indicate a low potential for abuse when modafinil is used alone, however there is
some evidence to suggest exposure to modafinil in combination with cocaine
(Schmitz, Rathnayake, Green, Moeller, Dougherty & Grabowski, 2012) or after
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repeated exposure to cocaine (Andersen, Kessler, Murnane, McClung, Tufik &
Howell, 2010) may make an individual more susceptible to relapse. Moreover,
results of clinical studies investigating modafinil as a potential agonist
replacement therapy have yielded mixed results (Hart, Haney, Vosuburg, Rubin,
& Foltin, 2008; Anderson et al., 2012).
In a sample of eight participants (one female and seven male AfricanAmericans) with a history of cocaine abuse, modafinil attenuated cocaine selfadministration as well as subjective measures of craving in controlled laboratory
conditions (Hart et al., 2008). In an earlier study, subjective ratings of cocaineinduced euphoria were attenuated by modafinil administration in cocainedependent participants (Dackis, Lynch, Yu, Samaha, & Kampman, 2003). In
addition, a trend toward attenuation of the subjective effects of
methamphetamine was observed after modafinil administration in 13
methamphetamine-dependent individuals not seeking treatment (De La Garza,
Zorick, London, & Newton, 2010). These participants made fewer choices for
methamphetamine during self-administration sessions. However, double-blind
placebo controlled studies with larger samples have yielded inconsistent findings.
One study evaluating modafinil for the treatment of methamphetamine
dependence found no significant differences between modafinil and placebo on
subject-rated cravings or methamphetamine use (Heinzerling, Swanson, Kim,
Cederblom, Moe, Ling, & Shoptaw, 2010). Anderson et al. (2012) evaluated
modafinil (200 and 400 mg/kg) as a treatment for cocaine dependence and found
no statistically significant differences between placebo and modafinil.
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Interestingly, when alcohol-dependent subjects were excluded from this analysis,
significant differences were reported on the number of cocaine abstinent days.
Preclinical Studies
Although clinical observations seem to indicate modafinil has a relatively
low abuse liability even in people with a history of psychostimulant dependence,
an extensive evaluation of its reinforcing effects utilizing standard preclinical drug
screening procedures may be warranted before promoting its use in a population
with a substance abuse history. To date, only a few preclinical studies have
evaluated modafinil in abuse liability screening procedures, such as behavioral
sensitization, conditioned place preference (CPP), drug discrimination, and drug
self-administration.
Locomotor Activity and Behavioral Sensitization
Locomotor activity is a measure commonly utilized in drug screening that
elucidates the motor effects of a drug. More importantly, this screening procedure
may elucidate similarities in the mechanism of action between known drugs of
abuse and novel compounds (Curzon, Zhang, Radek, & Fox, 2009). Studies
investigating the locomotor activating effects of modafinil have found both no
effect and increases compared to baseline or control groups. No increases in
activity were reported in Syrian hamsters (Webb, Pollock, & Mistelberger, 2006)
or in fruit flies (Hendricks, Kirk, Panckeri, Miller, & Pack, 2003). However,
modafinil-induced increases in activity were reported in the bungalow test and
human threat test in Marmoset monkeys (Van Vilet, Jongsma, Vanwersch,
Olivier, & Philippens, 2006) and increases in nighttime activity were reported in
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Rhesus monkeys (Andersen et al, 2010). Studies utilizing rats have reported
increases in general activity (Zolkowska, Jain, Rothman, Partilla, Roth, Setola,
Prisinzano, & Baumann, 2009) and movement in the Morris water maze (Ward et
al., 2004), while examination of sensitization in mice has yielded results
consistent with the other rodent studies. Specifically, activity and exploratory
rearing movements were increased after modafinil administration (Young,
Koolstra, & Geyer, 2011). Together these studies indicate modafinil may have
motor activating effects in monkeys, mice, and rats although there is no
promising evidence utilizing other species.
Behavioral sensitization is a paradigm that incorporates measures of
locomotor activity after a period of repeated exposure to a test compound
followed by a washout period. A challenge session with a lower dose of the test
compound or a different test compound follows the washout period. An increase
in activity after the challenge dose that is increased above the levels obtained on
the first day of drug administration is indicative of neuroadaptive changes in the
mesotelencephalic dopamine pathway (Louk, Vanderschuren, & Kalivas, 2000)
and deemed sensitization. The incentive sensitization theory states that these
neuroadaptive changes culminate in hypersensitivity to the stimuli associated
with the drug and may account for the drug “wanting” effects observed in
substance users. When this effect is paired with executive functioning deficits,
the major symptoms of addiction are observed (Robinson & Berridge, 2000).
There are two different measures used to assess behavioral sensitization.
Induction of sensitization is displayed when the response to the drug increases
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with repeated exposure. Expression of sensitization is demonstrated by an
increased response on the challenge day, which typically occurs after a washout
period, compared to the response on day one of drug exposure. Crosssensitization often occurs to drugs in the same drug class (Stewart & Bdiani,
1993) although cross-sensitization can occur between drugs of distinct
pharmacological classes (Valjent, Bertran, Gonzalez, Aubier, Greengard, Herve,
& Girault, 2010). For example, caffeine pre-exposure has been shown to
sensitize rats to the locomotor activating effects of cocaine (Schenk, Horger, &
Snow, 1990). These authors suggest exposure to other legal or prescription
stimulants may prime nervous system responsivity to cocaine.
Studies utilizing the sensitization assay with modafinil have reported
results indicative of sensitization or cross-sensitization. One study found no
evidence of behavioral sensitization in mice repeatedly exposed to a high or low
dose of modafinil when presented with a challenge dose of the same drug
(Shuman et al., 2012). In contrast, studies utilizing the same species have
demonstrated induction of sensitization with a single dose of modafinil (64 mg/kg,
i.p.) (Wuo-Silva et al., 2011) and expression of sensitization to a challenge dose
of modafinil (75 mg/kg, i.p.) following repeated treatment with a higher modafinil
dose (150 mg/kg) (Paterson, Fedolak, Olivier, Hanania, Ghavami & Caldarone,
2010). Cross-sensitization investigations have found expression of sensitization
with a challenge dose of cocaine after only two days of exposure to modafinil
(Wuo-Silva et al., 2011). Investigations of modafinil in combination with other
psychostimulants demonstrate sensitization with a combination of cocaine and
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modafinil although these effects were not significantly different from the effects of
cocaine alone (Shuman et al., 2012). Cross-sensitization was produced after a
challenge dose of modafinil in cocaine-pretreated mice (Shuman et al., 2012)
and a subgroup of methamphetamine pretreated mice (Da Costa Soeiro,
Moreira, Abrahao, Quadros, & Oliveira, 2012). Likewise, cross-sensitization to a
challenge dose of methamphetamine was reported in a subgroup of mice after
repeated exposure to modafinil (Da Costa Soeiro et al, 2012). Additive effects
between modafinil and cocaine were also shown to develop robust induction and
expression of sensitization to cocaine (Wuo-Silva et al., 2011). It is noteworthy to
mention that sensitization to modafinil, unlike that of methamphetamine, was
context-dependent and only expressed in the context in which drug
administration occurred (Da Costa Soeiro et al., 2012).
Place Conditioning/Conditioned Place Preference
The conditioned place preference paradigm is a preclinical screening
assay widely used to assess drug-induced conditioned reward by testing the
amount of time an animal spends in a drug-paired chamber after several pairings
between the drug and a distinct environmental context. It is well documented
that many drugs of abuse readily establish a CPP (Bardo, Rowlett, & Harris,
1995) in a variety of species including amphibians (Presley, Lonergan, & Chu,
2010), crayfish (Alcaro, Panksepp, & Huber, 2011), and rodents (Bardo et al.,
1995). This assay utilizes Pavolvian conditioning strategies by pairing a drug
with a specific, salient context repeatedly, while pairing the absence of drug with
another, salient context. On the test day, the animal is placed in the chamber
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and can freely move about both environments. Time spent in both compartments
is measured and if the animal spends significantly more time in the drug-paired
context, the drug is considered to have rewarding properties (Bardo & Bevins,
2000).
Evaluation of modafinil in place conditioning procedures has yielded
somewhat inconsistent findings. For example, Deroche-Gamonet et al. (2002)
assessed a range of modafinil doses (32-256 mg/kg) administered via
intraperitoneal (i.p.) injection, none of which reliably established CPP in rats. In
contrast, it was reported that 64 mg/kg (i.p.) (Wuo-Silva et al., 2011) and 125
mg/kg (i.p.) (Nguyen, Tian, You, Lee, & Jang, 2011) modafinil established CPP in
mice. Besides species differences, a number of methodological differences
between these studies could account for the discrepant findings, such as number
and length of habituation sessions, the cues used in the chambers, and drug
pretreatment time.
Drug Discrimination
Drug discrimination is a widely accepted preclinical behavioral assay
predictive of pharmacological mechanisms of drug action and is frequently used
to examine drug interactions. In this paradigm, animals are trained to
discriminate between at least two compounds, typically a drug and vehicle
condition, and responses on one of two levers are reinforced, with each lever
paired with a particular discriminative stimulus condition. After acquisition of the
discrimination, other compounds are tested for stimulus generalization or
stimulus antagonism to the training drug. This procedure can be used to assess
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many characteristics of a drug that include dose-response curves, rate effects,
generalization, and pharmacological mechanism of action (Glennon & Young,
2011).
To date, modafinil has been investigated in five published drug
discrimination studies with nonhumans. In the first of these studies,
generalization was assessed in six rats trained to discriminate 10 mg/kg cocaine
(Gold and Balster, 1996). Modafinil produced dose-dependent increases in
cocaine-lever selection, but group data yielded only partial substitution (67%) at
doses that significantly suppressed responding. However, it is noteworthy that
four of the six rats exhibited complete stimulus generalization to cocaine
following administration with 250 mg/kg modafinil in that study. More recently, an
investigation utilizing Rhesus monkeys found that modafinil substituted for low
(0.18 mg/kg i.m.) and high (0.4 mg/kg i.m.) training doses of cocaine (Newman,
Negus, Lozama, Prisinzano, & Mello, 2010). Paterson et al. (2010) reported full
substitution with 300 mg/kg modafinil and partial generalization after 100 mg/kg
modafinil in rats trained to discriminate 10 mg/kg cocaine. Moreover, Loland,
Mereu, Okunola, Cao, Prisinzano, Mazier, Kopajtic, Shi, Katz, Tanda & Newman
(2012) found that a much lower dose (56 mg/kg) and a similar dose (100 mg/kg)
of modafinil and both modafinil enantiomers fully substituted for cocaine in mice
trained to discriminate 10 mg/kg cocaine. In all of these studies, cocaine and
modafinil were administered by intraperitoneal injection. Dopheide, Morgan,
Rodvelt, Schachtman & Miller (2007) tested modafinil (32, 64, 128 mg/kg)
administered by oral gavage at various post-injection times (10 to 240 min) in
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three groups of male Sprague-Dawley rats trained to discriminate one of two low
doses of cocaine (1.6, 5 mg/kg, i.p.) or a single dose of d-amphetamine (0.3
mg/kg, s.c.). They also tested 32 mg/kg modafinil in combination with a range of
cocaine and d-amphetamine doses in all three groups of rats. Partial substitution
was seen with 64 mg/kg and 128 mg/kg modafinil in both cocaine training dose
groups and the d-amphetamine training group. Although modafinil alone failed to
fully substitute for cocaine or d-amphetamine in that study, 32 mg/kg modafinil
enhanced the discrimination of low doses of cocaine and d-amphetamine and
shifted the dose-effect curves to the left. These findings suggest that modafinil
may have additive effects with other stimulants.
Self-Administration
The self-administration paradigm is considered the golden standard
paradigm in addiction research for assessing abuse liability and involves utilizing
a drug as the reinforcer for lever pressing behavior. This procedure can also be
used to investigate whether pretreatment with pharmacological compounds
attenuates the rate of drug-taking behavior. This is useful for evaluation of
candidates for agonist replacement therapies and has relevance to treatment in
the clinical population of drug-dependent individuals (Haney & Spealman, 2008).
The first self-administration study utilizing modafinil was reported by Gold
and Balster (1996) and demonstrated that 0.3 mg/kg modafinil substituted for
cocaine in three rhesus monkeys that had been previously trained to selfadminister cocaine. The number of modafinil infusions was comparable to or
greater than the number of cocaine infusions by the same animals, although a
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larger dose of modafinil was required to produce effects similar to that of cocaine.
In contrast, Deroche-Gamonet et al. (2002) reported that modafinil did not
substitute for cocaine self-administration in rats, nor did it induce reinstatement
(described below) after cocaine self-administration was extinguished.
Reinstatement of Drug-Seeking
The reinstatement paradigm has been used as an animal model of drug
relapse and craving (Andersen et al., 2010) and can be evaluated after extinction
of a conditioned place preference or drug maintained responding in the selfadministration paradigm. After a response in either of these assays is
extinguished, a cue or drug is presented and the response is measured.
Reinstatement is said to occur if the response level is similar to the response
obtained prior to extinction. Experiments utilizing these paradigms have
demonstrated modafinil-induced reinstatement of extinguished
cocaine-maintained responding (Andersen et al., 2010) in the self-administration
paradigm as well as modafinil-induced reinstatement of an extinguished cocaine
place preference (Bernardi, Lewis, Lattal, & Berger, 2009). In the selfadministration paradigm, 10 mg/kg modafinil reinstated responding in Rhesus
monkeys trained to self-administer 0.1 mg/kg cocaine intravenously (i.v.)
(Anderson, Reid, Shou-Hua, Holmes, Shemanski, Slee & Elkashef, 2009), while
32 mg/kg and 56 mg/kg modafinil reinstated behavior maintained by a higher
dose of cocaine (0.4 mg/kg, i.m.) in the same species (Newman et al., 2010).
Treatment with 0.3 mg/kg modafinil did not significantly increase responding
compared to placebo (Anderson et al., 2009).
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In methamphetamine-trained rats, modafinil alone injected i.p. (Reichel &
See, 2010) or i.v. (Holtz, Lozama, Prisinzano, & Carroll, 2012) did not reinstate
self-administration of methamphetamine. Interestingly, when modafinil was
administered prior to methamphetamine-primed reinstatement conditions, it
dose-dependently attenuated the reinstatement of lever pressing. The highest
dose of modafinil attenuated the methamphetamine-primed reinstatement of
lever pressing most robustly (Reichel & See, 2010). This phenomenon was
replicated in methamphetamine-trained rats, but only one dose of modafinil was
tested, which attenuated the methamphetamine paired responding (Holtz et al,
2012). Moreover, chronic modafinil administration during extinction of
methamphetamine maintained responding attenuated cue-primed and
methamphetamine-primed reinstatement (Reichel & See, 2012). In addition, a
challenge test with methamphetamine two weeks after modafinil treatment
ceased resulted in lower drug responding compared to control, indicating chronic
modafinil treatment has enduring effects (Reichel & See, 2012).
Modafinil’s effects in the place conditioning reinstatement paradigm
appear to depend on the particular drug utilized to establish CPP. TahsiliFahadan, Carr, Harris, and Aston-Jones (2010) reported that 300 mg/kg
modafinil completely blocked a morphine-primed reinstatement of morphine
place preference. In contrast, following extinction of cocaine-induced place
preference, 128 mg/kg modafinil has been reported to reinstate a place
preference (Bernardi, et al., 2009). Evidence from this paradigm suggests
modafinil may not be a promising agent for therapeutic use in psychostimulant
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abusers and dependent individuals, although evidence from many other assays
suggest the opposite (Paterson et al., 2010, Dopheide et al., 2007). Research
investigating modafinil’s mechanism of action provides further support for the use
of modafinil as an agonist replacement therapy.

Modafinil’s Pharmacological Mechanisms of Action
Discerning the neuropharmacological actions of modafinil is essential to
fully understanding its behavioral effects and its potential clinical utility. The
remainder of the literature review therefore emphasizes research findings based
on various assays utilized to discover modafinil’s neurochemical mechanisms of
action. Investigations of the neuropharmacological actions of drugs are
performed using a variety of different assays and populations. Some of the in
vitro techniques that have been utilized to study modafinil’s neurochemical
actions include competitive receptor binding assays and measures of
spontaneous and electrically-evoked release of neurotransmitters in brain tissue
slices. Other procedures include electrophysiology to assess neural firing and in
vivo microdialysis to assess localized drug-induced changes in neurotransmitter
or metabolite levels in specific brain regions in either anesthetized or awake
animals. Drug discrimination offers an alternative in vivo approach to
investigating the neuropharmacological actions of drugs. As noted above, this
approach involves establishing a drug as a discriminative stimulus and assessing
other substances for stimulus generalization or antagonism. One advantage of
the drug discrimination procedure over neuropharmacological assays is that it is
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conducted in a live behaving animal. Moreover, this assay is pharmacologically
specific and has considerable predictive validity. Nevertheless, a potential
limitation of the drug discrimination procedure is that neural mechanisms of drug
action must be inferred rather than measured directly. Collectively, a wide variety
of in vitro and in vivo techniques can be used to provide converging evidence
regarding drug mechanisms of action.
Research exploring modafinil’s neuropharmacological actions has
implicated several neurotransmitter systems, including serotonin (5-HT), orexin,
norepinephrine (NE) and dopamine (DA) (Dopheide, et al., 2007; Minzenberg &
Carter, 2008; Wisor, Nishino, Sora, Uhl, Mignot, & Edgar, 2001; Zolkowska et al.
2009). Most evidence of 5-HT involvement results from investigations utilizing
microdialysis or receptor and transporter binding assays. In these binding
assays, modafinil enhances electrically evoked, but not spontaneous 5-HT
release in rat frontal cortical slices (Ferraro, Fuxe, Tanganelli, Fernandex,
Rambert, & Antonelli, 2000), while Loland et al. (2012) found no measurable
binding of modafinil to the serotonin uptake inhibitor. Microdialysis studies in the
awake rat found that modafinil produced dose-dependent increases of 5-HT
release in the frontal cortex, without affecting the release of 5-HT from the
synaptic vesicles or blocking reuptake in the behaving rat (Ferraro et al., 2000)
and increased levels of 5-HT in the frontal cortex, amygdala, and dorsal raphe
nucleui in the brainstem (Ferraro, Antonelli, Tanganelli, O’Connor, de la Mora,
Mendez-Fanco, Rambert, & Fuxe, 1999). However, modafinil appears to have a
very weak effect or no effect on the 5-HT levels in the nucleus accumbens
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(Zolkowoska et al., 2009). These regional differences in the serotonergic actions
of modafinil could possibly account for its cognitive-enhancing effects due to
actions in the frontal cortex as well as explain the lack of reinforcing effects
typically attributed to the nucleus accumbens.
Research on the involvement of the orexin and histamine systems in
modafinil’s actions was initiated based on knowledge that narcolepsy is
associated with a deficiency in these peptide systems (Nishimo, Ripley,
Overeem, Lammers, & Mignot, 2000). An increase in Fos-IR neurons, which
represents currently active neurons, was seen in the tuberomammilary nucleus
following oral administration of modafinil (75 and 100 mg/kg) administration in the
rat (Scammell, Estabrooke, McCarthy, Chemelli, Yanagisawa, Miller & Saper,
2000). However, modafinil injections directly into the rat tuberomammillary
nucleus produced no change in histamine release (Ishizuka, Sakamoto, Sakurai,
& Yamatodani, 2003), indicating the histaminergic system does not directly
account for modafinil’s effects.
The noradrenergic system has also been implicated in modafinil's
neurochemical effects. Pretreatment with prazosin, an alpha-1 adrenergic
antagonist, blocked the locomotor activating effects of modafinil in rhesus
monkeys (Hermant et al., 1991), reversed the modafinil-induced increase in brain
temperature (Lin et al., 1992), partially attenuated the wake promoting effect of
modafinil measured by EEG in the cat brain (Lin et al., 1992), and attenuated the
locomotor activating effect of modafinil in a control group of wild type mice
(Mitchell et al., 2008). Pretreatment with yohimbine, an alpha-2 receptor
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antagonist, on the other hand, enhanced the wake-promoting and temperature
increasing effects of modafinil, while β-receptor antagonists moderately
decreased these same effects of modafinil (Lin et al., 1992). Although these
results suggest the NE system is heavily involved in the neurochemical actions of
modafinil, other research has found conflicting results. An in vitro study in the rat
brain, examining the effect of prazosin on modafinil-induced firing in the ventral
tegmental area found no difference from control when modafinil was presented
alone (Korotkova, Klyuch, Ponomarenko, Lin, Haas, & Sergeeva, 2007) and in an
investigation of norepinephrine transporter binding, no binding was seen after
modafinil administration in human COS-7cells (Loland et al., 2012). These results
point to a potential role of alpha-1 receptors and possibly a role for β-receptors,
but imply that the norepinephrine transporter system is not involved in the
behavioral effects of modafinil, while alpha-2 receptor antagonism may result in
additive effects when combined with modafinil.
Most psychostimulant drugs produce their effects by elevating DA levels in
the central nervous system and some authors have suggested that because
modafinil lacks the behavioral effects typically seen with traditional
psychostimulants, it does not work through the DA system (Engber, Dennis,
Hones, Miller, & Contreras, 1998). However, more recent research utilizing
genetic modification models, microdialysis and in vitro binding assays has
demonstrated that modafinil does, in fact, exert effects on the dopaminergic
system (Loland et al., 2012; Murillo-Rodriguez, Haro, Palomero-Rivero, MillanAldaco, & Drucker-Colin, 2007; Qu, Huang, Xu, Matsumoto & Urade, 2008;
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Volkow et al., 2009). For example, in a study utilizing dopamine-b-hydroxylase -/(Dbh-/-) mice, which have virtually no NE in the CNS and hypersensitivity to DA,
demonstrated increased sensitivity to the behavioral activating effects of
modafinil (Mitchell et al., 2008). In addition, a microdialysis study demonstrated
increases in extracellular DA in the nucleus accumbens shell after modafinil
administration (Murillo-Rodriguez et al., 2007). Another study utilizing in vitro
binding assays in human brain tissue reported decreased binding potential for
[11C]-raclopride after modafinil administration in the caudate, putamen, and
nucleus accumbens, indicative of increased DA binding (Volkow, Fowler, Logan,
Alexoff, & Zhu, 2009). Binding assays in other populations have demonstrated
that modafinil (31.25, 62.5, 125 mg/kg, i.p.) treatment significantly increases D1
DA receptor binding compared to controls in the mouse caudate putamen, the
nucleus accumbens, and the substantia nigra (Nguyen et al., 2011). Increased
D2 binding in the mouse caudate putamen, nucleus accumbens (Nguyen et al.,
2011) and rat ventral tegmental area, and substantia nigra (Korotkova et al.,
2007) following modafinil administration were reported in similar assays.
Another study evaluating the role of D2 receptors in modafinil’s actions
reported that modafinil does not function as a wake-promoting agent in D2
receptor knockout mice (Qu et al., 2008). In addition, differences after
administration of a D2 antagonist, raclopride, at both low and high doses
attenuated the modafinil-induced increases in EEG functions (Qu et al., 2008)
although the locomotor activating effects were not completely abolished (Qu et
al., 2008). However, in an earlier study the D2 dopamine receptor antagonist,
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haloperidol, did not weaken the locomotor activating effect of modafinil in mice
(Simon, Hemet, Ramassamy, & Costentin, 1995). Investigation of modafinilinduced D1 receptor activation reported decreased wakefulness after
administration of modafinil and a D1 antagonist, SCH23390, at a low dose. (Qu et
al., 2008). Together, this evidence suggests both D1 and D2 receptors are
necessary for the wake-promoting effects of modafinil, although D2 receptor
activation may not be necessary for its locomotor activating effects and the role
of the D1 receptor is uncertain.
Other studies involving in vivo assays indicate that modafinil may indirectly
affect brain DA systems. Evidence suggests that interference with the DA
reuptake (i.e., the dopamine transporter) system can prevent the effects on EEG
readings induced by modafinil in a cat model (Lin et al., 1992). Furthermore, in
dopamine transporter (DAT) knockout mice, the wake-promoting effects of
modafinil were not seen, indicating the DAT is necessary for the wakefulness
effect of modafinil (Wisor et al., 2001). Furthermore, when rats are pretreated
with the DAT inhibitor, nomifensine, modafinil-induced dopamine overflow in
striatral brain slices is eliminated (Dopheide et al., 2007). In addition to these
investigations, Zolkowska et al. (2009) reported that pretreatment with modafinil
decreased methamphetamine- induced dopamine release in male SpragueDawley rats indicating that the dopamine transporter is involved in its primary
mechanism of action.
Investigations utilizing in vitro techniques to assess modafinil-induced DAT
binding also produce results that strongly suggest DAT involvement in modafinil’s
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effects. Binding studies have found modafinil administration results in 60 % DAT
occupancy in cells from Rhesus monkeys (Anderson et al., 2009) and 64 %
occupancy of the DAT in the putamen and 60% in the caudate in human cells
(Loland et al., 2012). Evidence demonstrating increased binding to the DAT in
the rat prefrontal cortex, caudate putamen, and nucleus accumbens after
modafinil administration (Nguyen et al., 2011) and decreased binding potential of
[11C]-cocaine after modafinil administration in PET measures of DA efflux in the
human brain, which reflects DAT occupancy (Volkow et al., 2009) supports the
claim that modafinil exerts its actions through the DAT.
Traditional psychomotor stimulants exert effects by stimulating the
monoamine system, in particular DA (Boutrel & Koob, 2004). Cocaine and
methamphetamine both function by inhibiting the DAT, while d-amphetamine acts
as a vesicle DA releaser (Boutrel & Koob, 2004). Given the similar receptor
mechanisms underlying the central nervous system actions of modafinil and
psychomotor stimulants, a thorough evaluation of modafinil’s abuse liability is
warranted.

Aims
The aim of this study was to evaluate the abuse liability of modafinil alone
and combined with d-amphetamine in three preclinical behavioral assays. Four
experiments were conducted to this end. The aim of the first experiment was to
evaluate the locomotor activating effects of repeated d-amphetamine treatment
and cross-sensitization of modafinil in male and female Sprague-Dawley rats.
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The second experiment examined a low dose combination of modafinil (64
mg/kg) and d-amphetamine (0.3 mg/kg) in comparison to each drug alone and to
a higher dose of d-amphetamine (2.0 mg/kg) using place conditioning procedures
in rats in an effort to evaluate the conditioned reward properties of the drug and
combination. The third study sought to replicate and expand the findings of
Dopheide et al. (2007) by testing modafinil alone and in combination with
d-amphetamine in rats trained to discriminate either a low dose (0.3 mg/kg) or
moderately high dose (1.0 mg/kg) of d-amphetamine. The aim of the fourth
experiment was to evaluate the combined effects of d-amphetamine and
modafinil in rats trained to discriminate 256 mg/kg modafinil from vehicle (5%
arabic gum) and to elucidate the pharmacological mechanism of action of
modafinil utilizing the drug discrimination paradigm.
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CHAPTER II
EXPERIMENT 1: d-AMPHETAMINE FAILS TO PRODUCE CROSSSENSITIZATION TO MODAFINIL IN SINGLY-HOUSED OR PAIR-HOUSED
MALE OR FEMALE RATS
Overview
Previous research has demonstrated sensitization and cross-sensitization
to modafinil after repeated treatment with modafinil (Paterson et al., 2010),
cocaine (Wuo-Silva et al., 2011), and methamphetamine (Da Costa Soeiro et al.,
2012). To date, no published data has investigated cross-sensitization to
modafinil after daily d-amphetamine treatment. This experiment sought to
determine if cross-sensitization would occur with a low challenge dose (64
mg/kg) of modafinil after repeated d-amphetamine treatment in male and female
individually- or pair-housed drug- naïve Sprague-Dawley rats. The housing
conditions were a result of previous experimental conditions and although both
male and female rats were utilized in this experiment, sex was not initially a
variable of interest.
Methods
Subjects
Eighteen male and 17 female drug naïve Sprague-Dawley rats (bred in
Western Michigan University’s animal colony) were utilized in this study. The
animals were singly- or pair-housed in polycarbonate cages with corncob
bedding where ad libitum access to food and water was available. Animals were
housed at Western Michigan University’s animal facilities in a humidity and
temperature-controlled room maintained on a 12:12 hour light/dark cycle with
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lights on at 7:00 a.m. All procedures were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals (National Academy of
Sciences, 2011) and were approved by the Institutional Animal Care and Use
Committee at Western Michigan University.
Apparatus
The apparatus consisted of six custom-designed open field chambers
constructed of acrylic (40.5 cm x 40.5 cm x 40.5 cm) and housed within an
Accuscan automated activity monitoring system (Accuscan Instruments, Inc.,
Columbus, OH) equipped with infrared emitters and detectors connected to a
microprocessor. Measures of horizontal activity and vertical activity were
recorded.
Procedures
Singly-housed males (n = 10), pair-housed males (n = 8), singly-housed
females (n = 8), and pair-housed females (n = 7) were assigned to one of eight
custom-made chambers. The males were assessed during the two morning 30
min sessions and assigned to session and chamber in a counterbalanced order.
Females were assessed during the afternoon sessions and assigned to chamber
and session in a counterbalanced order. Within each group, the animals were
randomly assigned to receive d-amphetamine or saline treatment. Three 30
minute habituation sessions were conducted to acclimate the animals to the
apparatus and to obtain an accurate measure of baseline activity. For the next
five days, d-amphetamine (3 mg/kg s.c) or saline was administered immediately
prior to placement in the apparatus for 30 minutes. A 10 day washout period
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followed the repeated administration of d-amphetamine or saline, where animals
were confined to home cages and no experimentation was completed. On day
19, a challenge test was conducted with modafinil (64 mg/kg) in all animals and a
vehicle test was conducted in all animals on the following day. For these test
sessions, animals were injected immediately prior to placement in the chambers
for 90 minutes.
Drugs
Modafinil was synthesized in the laboratory of Dr. Thomas Prisinzano
using previously described methods (Prisinzano, Podobinski, Tidgewell, Luo, &
Swenson, 2004), prepared on the day of use by suspension in a 5% arabic gum
solution (Sigma Aldrich, St. Louis, MO) and administered by oral gavage (i.g.) in
a volume of 10 ml/kg. The d-amphetamine-hemisulfate (Sigma Aldrich, St. Louis,
MO) was suspended in a 0.9% NaCl solution and administered subcutaneously
(s.c) in a volume of 1 ml/kg. Doses were based on the weight of the salts.
Data Analysis
Separate statistical analyses were conducted for each group:
singly-housed males, pair-housed males, singly-housed females, and pairhoused females. Horizontal activity and vertical activity measures collected
during 30 min d-amphetamine or saline treatment sessions were analyzed
utilizing a repeated measures two-factor (drug treatment, treatment session)
ANOVA to investigate whether differences in drug treatments varied over
repeated dosing. Repeated measures two-factor (pretreatment, test drug)
ANOVAs were also conducted on horizontal and vertical activity measures
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obtained during the first 30 minutes of the 90 minute test sessions to determine if
pretreatment (d-amphetamine or saline) differentially influenced activity during
test session (modafinil or saline).

Results
Figure 1 depicts horizontal activity and Figure 2 represents vertical activity
during three 30 min habituation and five treatment sessions for all four groups,
with data for males in the upper panels and data for females in lower panels.
Data from singly-housed animals are depicted in the left panels and data from
pair-housed animals are presented in the right panels. As expected,
d-amphetamine treatment increased activity compared to habituation sessions
and compared to saline treatment. Statistical analyses are reported below for
each sex and housing group.
Assessment of Sensitization Induction
Single Males. A two-factor repeated measures ANOVA on horizontal activity
across test sessions revealed a main effect of drug that approached significance
[F(1, 8) = 4.50, p = 0 .06], in addition to a significant main effect of test session
[F(4, 32) = 7.52, p < 0.0001], and a significant drug x test session interaction
[F(4, 32) = 4.47, p < 0.01], although there were no significant Bonferroni post-hoc
tests (see Figure 1). Analysis of vertical activity with a repeated measures
ANOVA resulted in a significant main effect of drug [F(1, 8) = 5.70, p < .05] and
test session [F(4, 32) = 2.67, p = .05], although there was not a significant
interaction (see Figure 2).
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Paired Males. A two-factor repeated measures ANOVA on horizontal
activity revealed a significant main effect of drug [F(1, 6) = 17.89, p < 0 .001], test
session [F(4, 24) = 2.84, p < 0.05], but no significant drug x test session
interaction (see Figure 1). Analysis of vertical activity with a repeated measures
two factor repeated measures ANOVA found a significant drug effect, [F(1, 6) =
16.84, p < 0.001], but no significant test session main effect or drug x test
session interaction (see Figure 2).
Single Females. Analysis of horizontal activity with a two-factor repeated
measures ANOVA revealed a significant main effect of drug [F(1, 7) = 39.55, p <
0 .01], test session [F(4, 28) = 4.84, p < 0.001] although there was not a
significant drug x test session interaction (see Figure 1). A two-factor repeated
measures ANOVA on vertical activity also revealed a significant main effect of
drug [F(1, 7) = 28.19, p < 0 .001], test session [F(4, 28) = 5.75, p < 0.01], but no
significant interaction effects (see Figure 2).
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Paired Females. Analysis of horizontal activity with a two-factor repeated
measures ANOVA revealed a significant main effect of drug [F(1, 6) = 74.33, p <
0 .001], test session [F(4, 24) = 10.54, p < 0.010], and a significant drug x test
session interaction [F(4, 24) = 6.52 p < 0.001]. Bonferroni post-hoc tests revealed
a significant difference between the saline and d-amphetamine treated animals
on the first (p < 0.01) and second (p < 0.05) day of drug administration (see
Figure 1). A two-factor repeated measures ANOVA on vertical activity revealed a
significant main effect of drug [F(1, 6) = 8.30, p < 0 .05], test session [F(4, 24) =
6.92, p < 0.001], and a significant drug x test session interaction [F(4, 24) = 3.09
p < 0.05], although there were no significant Bonferroni post-hoc tests (see
Figure 2).
Evaluation of Cross Sensitization
Single Males. Figure 3 represents horizontal activity measures during the
modafinil and vehicle challenge days separated by pretreatment group (damphetamine or saline). Figure 4 displays the same information for vertical
activity measures. A repeated measures two (modafinil test vs. vehicle test) X
two (d-amphetamine vs. saline pretreatment) ANOVA on horizontal activity found
a significant effect of test drug, [F(1, 8) = 18.37, p < 0.01], but no main effect of
pretreatment. The same analysis of vertical activity showed similar results. There
was no main effect of pretreatment group, but a significant effect of test drug
[F(1, 8) = 10.53, p < 0.01]. There were no significant interaction effects.
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Paired Males. A repeated measures two-factor ANOVA on horizontal
activity following modafinil treatment found no main effect of pretreatment
condition, but did reveal a significant test drug main effect, [F(1, 6) = 17.55, p <
0.01] (see Figure 3). The same analysis with vertical activity revealed an effect of
pretreatment that approached significance [F(1,6) = 4.72, p = 0.07) and a
significant main effect of test session [F(1, 6) = 14.86, p < 0.01], although there
were no significant interaction effects (see Figure 4).
Single Females. A repeated measures two (modafinil test vs. vehicle test)
X two (d-amphetamine vs. saline pretreatment) ANOVA on horizontal activity
found a significant effect of test drug [F(1, 7) = 67.24, p < 0.001], but no main
effect of pretreatment or interaction (see Figure 3). The repeated measures
ANOVA on vertical activity found a pretreatment effect that was almost
significant, [F(1, 7) = 5.26, p = 0.055] and a significant effect of test drug [F(1, 7)
= 75.82, p < 0.001], although there were no significant interaction effects (see
Figure 4).
Paired Females. A repeated measures two-factor ANOVA on horizontal
activity found no main effect of pretreatment group, but did reveal a significant
effect test drug, [F(1, 5) = 60.57, p < 0.001] (see Figure 3). The repeated
measures ANOVA on vertical activity showed no effect of pretreatment, but there
was an effect for test drug F(1, 5) = 31.59, p < 0.01, but there were no significant
interaction effects (see Figure 4).
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Discussion
This experiment investigated the expression of cross-sensitization to a low
dose of modafinil following a brief history of daily repeated d-amphetamine
treatment and a 10 day washout period in singly- or pair-housed male or female
Sprague-Dawley rats. The results demonstrate that repeated d-amphetamine
treatment significantly increases horizontal and vertical activity, but this effect
decreases over five daily treatment sessions and thus, no induction of
sensitization was displayed. Although no statistically significant differences in
pretreatment with d-amphetamine or saline were seen, and thus no expression of
cross-sensitization, a modest increase in the locomotor activating effects of
modafinil was seen in some animals pretreated with d-amphetamine. Most
importantly, an increase in horizontal and vertical activity relative to vehicle was
shown in all groups following modafinil administration. Although there was no
evidence of induction of sensitization or expression of cross sensitization, this
study confirmed previous findings that modafinil administration at low doses can
induce an increase in locomotor activity (Zolkowska et al., 2009; Andersen et al,
2010; Van Vilet et al., 2006).
This is the first study to investigate the locomotor effects of modafinil
following repeated d-amphetamine treatment in any species, however previous
studies utilizing mice have demonstrated cross sensitization to modafinil
following treatment with cocaine (Shuman et al., 2012) or methamphetamine (Da
Costa Soeiro et al., 2012). Cross sensitization to acute modafinil pretreatment
has been also been demonstrated with a challenge dose of cocaine (Wuo-Silva
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et al., 2011). The results of the current study are somewhat surprising compared
to previous research findings. One assumption of the behavioral sensitization
paradigm is that drugs that produce cross-sensitization to each other have similar
neurochemical targets in the central nervous system (Stewart & Badiani, 1993).
The discrepancy between current results and this theoretical perspective along
with previous studies investigating modafinil sensitization could be due to
differences in the species utilized, route of administration, or doses of the test
compounds. In addition, the small number of subjects per group could account
for the lack of statistically significant effects of d-amphetamine pretreatment on
cross-sensitization to modafinil in the current study. It is also possible that
procedural differences, like treatment regime, between studies are responsible
for the discrepant results. This study utilized daily administration of
d-amphetamine or vehicle for 5 days, while other studies that have demonstrated
expression of cross-sensitization to modafinil utilized intermittent pre-exposure to
cocaine (Paterson et al., 2010) or methamphetamine (Shuman et al., 2012).
However, modafinil cross-sensitization was reported after 10 daily
methamphetamine injections (Da Costa Soerio et al., 2012) in one study
indicating that repeated daily treatment could result in cross sensitization.
Perhaps, a longer duration of exposure is necessary with daily drug
administration.
It is also possible that modafinil does not share a similar of a mechanism
of action with d-amphetamine. At least one study has demonstrated that D1
receptors are critical for d-amphetamine sensitization to occur, but not for
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cocaine sensitization to occur (Vanderschuren & Kalivas, 2000), which could
explain the discrepancy between findings. The role of DA receptors in modafinil’s
neurochemcal mechanisms of action was not assessed in this experiment, but
was examined utilizing a drug discrimination procedure in the experiments
described in Chapter 5.
Despite the lack of evidence for cross-sensitization between damphetamine and modafinil in this preliminary experiment, additional studies
were pursued to explore the behavioral effects of concurrent administration of
modafinil and d-amphetamine, in order to determine if these drugs exert additive
effects. Experiment 2 utilized a well-established preclinical assay of drug abuse
liability, conditioned place preference, and Experiments 3 and 4 utilized drug
discrimination procedures to evaluate the combined stimulus effects of these
drugs. The aim of Experiment 2 was to determine if combined low dose
administration of modafinil and d-amphetamine produced greater CPP than
either drug alone. The primary aim of Experiments 3 and 4 was to determine if
modafinil potentiated the discrimination of d-amphetamine or vice versa.
Evidence for additive effects of modafinil and d-amphetamine in these preclinical
assays could be informative regarding similarities in their mechanism of action
and have implications for the combined subjective effects of these substances in
humans.
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CHAPTER III
EXPERIMENT 2: MODAFINIL IN COMBINATION WITH LOW DOSE dAMPHETAMINE DOES NOT PRODUCE CONDITIONED PLACE
PREFERENCE
Overview
Few studies have examined modafinil in the place preference paradigm.
One study reported no evidence of place preference after i.p. administration of a
range of modafinil doses in rats (Deroche-Gamonet et al, 2002), whereas two
studies that used mice as subjects reported modafinil established CPP at low
(Wuo-Silva et al., 2011) and moderate (Nguyen et al., 2011) doses. This
experiment sought to systematically replicate the experiment designed by
Deroche-Gamonet et al. (2002) with an oral dose of modafinil in addition to
evaluating CPP with a combination of modafinil and d-amphetamine.
Methods
Subjects
Forty male Sprague-Dawley rats (Charles River Laboratories, Portage, MI)
50-60 days old at the start of the experiment were acclimated to the animal
facilities for at least one week prior to initiation of place conditioning experiments.
A separate group of 15 adult male Sprague-Dawley rats were assessed in a
supplemental experiment to determine the effects of 64 mg/kg modafinil on
locomotor activity. Animals were individually housed in polycarbonate cages with
corncob bedding where ad libitum access to food and water was available. All
animals were housed in Western Michigan University’s animal facilities in a
humidity and temperature-controlled room with a 12:12 hour light/dark cycle with
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lights on at 7:00 a.m. All procedures were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals (National Academy of
Sciences, 2011) and were approved by the Institutional Animal Care and Use
Committee at Western Michigan University.
Apparatus
The apparatus utilized for place conditioning and locomotor activity
assessments consisted of eight custom-designed open field chambers
constructed of acrylic and measuring 40.5 cm x 40.5 cm x 40.5 cm. For place
conditioning experiments, the chambers were divided into two-compartments
with an acrylic wall and removable 12.8 cm X 18 cm door. Each compartment
contained distinct visual and tactual cues. One compartment contained walls
covered with alternating vertical black and white stripes and a textured plastic
floor. The other compartment contained walls covered with alternating horizontal
black and white stripes and an aluminum floor with 1.1 cm diameter holes spaced
approximately 0.5 cm apart. Each chamber was housed within an Accuscan
automated activity monitoring system (Accuscan Instruments, Inc., Columbus,
OH) equipped with infrared emitters and detectors connected to a
microprocessor. Locomotor activity and time spent in each side of apparatus
were processed using Versamax software (Accuscan Instruments, Inc.,
Columbus, OH).
Procedures
Place Conditioning Trials. Thirty-two animals were randomly assigned to
one of the following four treatment groups: 5% arabic gum + 0.9% saline
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(VEH+SAL), 5% arabic gum + 0.3 mg/kg d-amphetamine (VEH+AMPH), 64
mg/kg modafinil + saline (MOD+SAL), 64 mg/kg modafinil + 0.3 mg/kg damphetamine (MOD+AMPH). These four groups were assessed during the same
consecutive 10 day period. Four squads of eight animals were run
simultaneously with two animals from each treatment group in each squad. For
comparison, a separate squad of eight animals was assessed for place
conditioning with 2.0-mg/kg d-amphetamine approximately one month later.
Assignments of test chamber and drug-paired compartment were
counterbalanced within and between treatment groups.
A single habituation session was conducted 24 hours prior to commencing
place conditioning. Animals were habituated to the entire test apparatus with the
doors removed for a period of 15 minutes. On the next day, place conditioning
commenced for eight days with a single 30-minute trial per day. During
conditioning, the removable doors were attached and rats only had access to one
compartment. On conditioning days 1, 3, 5, and 7, rats were administered their
respective drug treatments (see above) prior to placement into one compartment.
On conditioning days 2, 4, 6 and 8, all rats were administered both 5% arabic
gum and saline before placement into the opposite side of the chamber.
Modafinil or 5% arabic gum was administered 30 minutes before and damphetamine or saline was administered 10 min before placement into the
chambers. Horizontal activity was recorded during all conditioning trials.
CPP test. The test session was conducted 24 hours after the last
conditioning session. Rats were placed in the test apparatus for 15 min with the
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doors removed to allow access to both compartments. Horizontal activity and
time spent in each compartment was electronically recorded. During all phases of
the experiment the floors and walls of the apparatus were wiped down with a 35
% isopropyl alcohol solution after each rat was removed.
Acute Assessment of Locomotor Activity. A supplemental experiment was
conducted with 15 rats to assess the effects of 64 mg/kg modafinil on locomotor
activity. The walls and floors used in the place conditioning experiment were not
used for this assessment. Animals were administered 64 mg/kg modafinil by oral
gavage immediately before placement in the apparatus for a period of 60
minutes. Horizontal activity and vertical activity were determined from infrared
beam breaks.
Drugs
Modafinil was synthesized in the laboratory of Dr. Thomas Prisinzano using
previously described methods (Prisinzano, et al., 2004), prepared fresh each day
of use by suspension in a 5% arabic gum solution (Sigma Aldrich, St. Louis, MO)
and administered by oral gavage (i.g.) in a volume of 10 ml/kg. The damphetamine-hemisulfate (Sigma Aldrich, St. Louis, MO) was suspended in a
0.9 % NaCl solution and administered subcutaneously (s.c) in a volume of 1
ml/kg. Doses were based on the weight of the salts.
Data Analysis
A repeated measures two-factor ANOVA was conducted on horizontal
activity during conditioning sessions with treatment group as a between subjects
factor and conditioning trial as a within subjects factor. Bonferroni post-hoc tests
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were conducted for significant differences between specific treatment groups. For
each treatment group, paired t-tests were conducted on the time spent in the
drug-paired compartment and vehicle-paired compartment during the 15 min test
session. In the supplemental experiment to assess horizontal and vertical activity
over a 60 min period immediately following 64 mg/kg modafinil, a two way
repeated measures ANOVA was conducted with time as a within subjects factor
and treatment as a between subjects factor.
Results
Locomotor activity did not differ significantly among the treatment groups
during the 15 min habituation period prior to the onset of conditioning nor was
activity different among these groups during the vehicle conditioning trials (data
not shown). Figure 5 displays the mean (± S.E.M.) horizontal activity during 30
min drug conditioning trials for each treatment group. Both 0.3 and 2.0 mg/kg damphetamine substantially increased activity relative to vehicle, whereas 64
mg/kg modafinil did not. Although the MOD+ 0.3 AMPH combination produced
slightly greater activity than either drug alone during the first conditioning trial,
this enhancement was not observed on subsequent drug conditioning trials. A
two-way repeated measures ANOVA on horizontal activity during drug
conditioning trials revealed a significant main effect of treatment group [F(4, 35) =
33.79, p < 0.001], conditioning trial [F(3, 105) = 4.69, p < 0.01], and a significant
interaction between treatment group and conditioning trial [F(12, 105) = 2.41, p <
0.01]. Significant Bonferroni post-tests comparing treatment groups to vehicle
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and to modafinil on each of the four drug conditioning trials are shown with
symbols in Figure 5.
Prior to conditioning, there was no consistent preference among animals
for either compartment. Following conditioning trials, vehicle and modafinil
treatment groups did not show preference for either compartment, whereas both
d-amphetamine treatment groups and the MOD+AMPH treatment group showed
a preference for the drug-paired compartment. Figure 6 displays the mean (±
S.E.M.) time spent in each compartment on the test day for each treatment
group. Paired t-tests comparing time spent in the drug-paired compartment with
time spent in the vehicle-paired compartment were statistically significant for both
the 0.3 mg/kg d-amphetamine group (t(7)=3.84, p < 0.01) and the 2.0 mg/kg damphetamine group (t(7)=3.12, p < 0.05). The animals in the MOD + 0.3 AMPH
treatment group also spent more time in the drug-paired compartment following
conditioning trials, but the difference in time spent between drug and vehicle
compartments was not statistically significant in this group.
A supplemental experiment was conducted to confirm that oral
administration of 64 mg/kg modafinil is behaviorally active. Results of this
experiment, shown in Figure 7 indicate that modafinil-treated animals exhibited
increased horizontal and vertical activity at nearly all post-injection time intervals
compared to vehicle treated animals. A two way ANOVA revealed the effect of
modafinil on horizontal activity was not quite statistically significant [F(1,13) =
3.65, p = 0.078], although the main effect of time was statistically significant
[F(11,143) = 18.99, p <0.0001]. The main effects of modafinil treatment [F(1,13) =
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9.28, p = 0.01] and time [F(11,143) = 6.57, p <0.0001] on vertical activity were
both statistically significant.
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Discussion
Results of the current study indicate that a moderately low oral dose of
modafinil (64 mg/kg) does not establish conditioned place preference in adult
male Sprague-Dawley rats. These results are consistent with a previous report
that modafinil (32-256 mg/kg, i.p.) fails to establish CPP in rats (DerocheGamonet et al., 2002); although others have reported 64 mg/kg modafinil to
establish CPP in mice (Wuo-Silva et al., 2011). Besides the species difference,
several other methodological differences could account for discrepant findings.
For example, Wuo-Silva et al. (2011) conducted 10 minute conditioning trials 30
minutes after i.p. modafinil injection and both drug and vehicle trials were
conducted on the same day with a six hour intertrial interval. Deroche-Gamonet
et al. (2002) conducted 30 min conditioning trials immediately following i.p.
modafinil injection and drug and vehicle trials were separated by 24 hours. The
methods were modeled after those employed by Deroche-Gamonet et al. (2002)
with the exception that animals in the current study were administered i.g.
modafinil 30 minutes prior to 30 minute conditioning trials. Nevertheless, the
present findings confirm previous suggestions that modafinil has a low abuse
liability in drug naïve individuals, in contrast to most psychomotor stimulants
(Bardo et al., 1995).
Amphetamine-induced place preference in rodents is a well-established
phenomenon at doses ranging from 0.3 mg/kg to 3 mg/kg (Bardo et al., 1995;
Deroche-Gamonet et al., 2002) and the current results with d-amphetamine are
consistent with these findings. It is somewhat surprising that there was no
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evidence for the development of sensitization with repeated d-amphetamine
exposure in the current study. However, two important measures of activity that
typically display sensitization, vertical activity and stereotypy, were not assessed
due to constraints of the place conditioning apparatus in which locomotor activity
was assessed.
The lack of a significant difference in locomotor activity between modafinil
and vehicle treatment groups during drug conditioning trials suggests the
possibility that this low oral dose of modafinil was not behaviorally active.
Therefore, a supplemental experiment was conducted with a separate group of
rats to determine that i.g. administration of 64 mg/kg modafinil does increase
locomotor activity (see Figure 7 and 8). Results of this assessment are supported
by results of the preliminary experiment described in Chapter 2, that
demonstrated increased activity following modafinil administration in a within
subjects design (see Figure 3). The current assessment showed a visuallyevident increase in horizontal activity and a statistically significant increase in
vertical activity in modafinil-treated rats compared to vehicle-treated rats. As
noted above, vertical activity was not assessed during place conditioning trials,
but there was no evidence of an increase in horizontal activity after modafinil
administration. It is possible that confinement to one compartment during place
conditioning trials limited horizontal movement and masked any differences
between modafinil and vehicle treatment groups.
The current findings also established that concurrent administration of a
low oral dose of modafinil dose does not enhance the hyperlocomotor effects or
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CPP established by a low dose of d-amphetamine. There was a visually evident
trend toward additive acute locomotor effects of 64 mg/kg modafinil and 0.3
mg/kg d-amphetamine only on the first drug conditioning day. The lack of a
statistically significant increase in activity with repeated exposure and the lack of
evidence for enhanced CPP with this drug combination indicate these drugs do
not have additive effects, at least at low doses. These findings suggest that low
oral doses of modafinil will likely not enhance the behavioral or reinforcing effects
of psychostimulants. However, in consideration of previous reports that higher
modafinil doses significantly increase locomotor activity (Deroche-Gamonet et
al., 2002), the next experiment was designed to determine if dose-dependent
increases in the additive effects of modafinil and d-amphetamine are different
than effects obtained by either compound alone. A preclinical behavioral assay
sensitive to the combined effects of compounds, the drug discrimination
paradigm, was utilized.
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CHAPTER IV
EXPERIMENT 3: COMBINED EFFECTS OF MODAFINIL AND
d-AMPHETAMINE IN MALE SPRAGUE-DAWLEY RATS TRAINED TO
DISCRIMINATE d-AMPHETAMINE
Overview
The specific aim of Experiment 3 was to evaluate the combined effects of
d-amphetamine and modafinilin a drug discrimination assay. This assay has
been used to evaluate changes in dose-response functions as a result of pretreatment with drugs with similar mechanisms of action to the training drug.. In
this paradigm, increased potency is demonstrated by a curve shift to the left. At
the time of this research, only one published study had evaluated modafinil in
combination with another substance in this assay. Dopheide et al. (2007) tested
modafinil (32, 64, 128 mg/kg) at varied post-injection times (10 to 240 min) in rats
trained to discriminate cocaine (1.6, 5 mg/kg, i.p.) or d-amphetamine (0.3 mg/kg,
s.c.). Subsequently, they examined the effects of modafinil in combination with
cocaine or d-amphetamine. Although modafinil alone only partially substituted for
cocaine and d-amphetamine, 32 mg/kg modafinil enhanced the discrimination of
low doses of cocaine and d-amphetamine and shifted the dose-effect curves to
the left, which suggests modafinil may have additive effects when used in
combination with other psychostimulants. The present experiment evaluated the
combined effects of modafinil and d-amphetamine in two groups of rats trained to
discriminate 0.3 mg/kg or 1.0 mg/kg. In addition, a positive control (PNU-91356A)
and two negative control conditions (morphine, ethanol) were tested to ensure
reliability of discrimination.
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Methods
Subjects
Sixteen male Sprague-Dawley rats (Charles River, Portage, MI)
approximately four months old and drug naïve at the beginning of the study were
utilized. All animals were housed individually in polycarbonate cages lined with
corncob bedding in a colony room with a 12:12 light/dark cycle with lights on from
7:00 a.m. to 7:00 p.m. Water and food were provided ad libitum during the
acclimation phase. The animals’ weight was then restricted to 80% of their freefeeding weight by restricting the amount of food given each day until the goal
weight was reached. All procedures were reviewed and approved by the Western
Michigan University Institutional Animal Care and Use Committee and were in
accordance with the guidelines of the Guide for the Care and Use of Laboratory
Animals (National Academy of Sciences, 2011).
Apparatus
Training and testing sessions were conducted in eight standard operant
conditioning chambers (ENV-001; MED Associates Inc., Georgia, VT, USA),
housed within sound- and light- attenuating shells. Each chamber was equipped
with three removable levers located on the front panel, a food pellet dispenser, a
28-V house light, and fan. Forty-five mg food pellets served as the reinforcers
(Bioserv; Frenchtown, NJ). Experimental events were programmed and
controlled using Version IV Med-PC software (MED Associates Inc., St. Albans,
VT, USA).

57
Drugs
d-Amphetamine-hemisulfate (Sigma-Aldrich, St. Louis, MO) was dissolved
in a 0.9% NaCl saline solution and administered s.c. Modafinil was synthesized
in the laboratory of Dr. Thomas Prisinzano using previously described methods
(Prisinzano, et al., 2004). Suspensions were prepared fresh each day in a 5%
arabic gum solution (Sigma Aldrich, St. Louis, MO) and administered by oral
gavage (i.g.) in a volume of 10 ml/kg 30 minutes prior to test sessions. Morphine
(Sigma-Aldrich, St. Louis, MO) and PNU-91356A (Pharmacia & Upjohn, Inc.,
Kalamazoo, MI) were dissolved in 0.9% NaCl and administered s.c. 10 minutes
prior to test sessions. Ethanol (Aaper Alcohol and Chemical Co., Shelbyville, KY)
was diluted in sterile water and administered i.g. in a volume of 10 ml/kg 10
minutes prior to test sessions.
Procedures
Preliminary Training. Initial training consisted of a single one hour session
with no levers present and rats were exposed to a fixed-time 60 second schedule
of food delivery to acclimate them to the sound and location of food pellet
delivery. All subsequent training sessions lasted 20 minutes and were conducted
once per day, five to six days a week between 4:00 and 6:00 p.m. All rats were
initially reinforced for responses on the center lever via an autoshaping program
under a continuous reinforcement schedule for one (n=9) or two (n=7) 20 min
sessions. Only the center lever was present during autoshaping sessions. Once
all animals were reliably lever pressing, errorless training commenced with only
the left or right lever present.
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Drug (D) or vehicle (V) injections were administered subcutaneously10
minutes prior to errorless training sessions. Drug injections consisted of 0.3
mg/kg d-amphetamine for one group (n=8) and 1.0 mg/kg d-amphetamine for the
other group (n=8) and vehicle injections consisted of 0.9% saline for both groups.
For half the animals in each group, errorless training sessions with only the right
lever present followed drug injections and errorless training sessions with only
the left lever present followed saline injections. Conditions were reversed for the
remaining animals in each group. All rats were exposed to twelve errorless
training sessions in the following order: V, V, D, D, V, D, D, V, D, V, V, D.
Responses were initially reinforced under a fixed-ratio 1 (FR 1) schedule and the
FR value was gradually incremented within each training session and across the
six errorless training sessions with each stimulus condition. Within each session,
the FR was programmed to increment by a designated amount (e.g., 1, 2, or 5)
after the delivery of five reinforcers at a particular FR value. Across training
sessions, the starting FR value was determined for each individual rat by the last
FR value obtained in the previous session. All rats were responding on a FR 20
schedule by the last errorless training session with each stimulus condition.
Discrimination Training Procedures. Immediately following the completion
of errorless training, discrimination training commenced with both levers present.
The first session with both levers present was designated as day one for
determining the number of training sessions required for each animal to meet the
discrimination criteria. Similar to errorless training sessions, discrimination
training under each stimulus condition began on a FR 1 schedule and the FR
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was increased gradually until the final FR 20 was reached under each stimulus
condition. Once animals were reliably responding on an FR 20 schedule under
both stimulus conditions, the FR 20 remained in effect for subsequent training
and the remainder of the study.
Drug and saline training sessions were administered in a pseudo-random
order, with the limitation that no animal received more than two consecutive drug
or two consecutive saline sessions throughout the study. For example, within a
six day period, drug (D) and vehicle (V) training sessions occurred in one of the
following orders: VVDDVD, DVDVVD, DVVDDV, DDVDVV, or DDVDDV. Levers
corresponding to stimulus conditions were held constant for each animal
throughout the entire study. Consistent with errorless training conditions, half of
the rats in each training group were reinforced for right lever responses following
d-amphetamine injections and for left lever responses following saline injections;
conditions were reversed for the remaining rats in each group. The chambers
and levers were wiped clean with isopropyl alcohol after each session to reduce
the influence of olfactory stimuli on lever selection (Extance and Goudie, 1981).
The criteria for stimulus discrimination required animals to emit a minimum of
80% correct lever responses prior to the delivery of the first reinforcer and for the
remainder of the training session for at least 8 of 10 consecutive discrimination
training sessions.
Testing Procedures. Stimulus generalization tests commenced
when each subject met the criteria described above. In between test sessions,
animals were administered no less than one drug training session and one
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vehicle training session and were required to exhibit 80% response accuracy on
the first FR as well as during the total session under both conditions to continue
testing. If an animal did not meet these criteria, training sessions continued until
criterion was met with each stimulus condition on two consecutive days.
Generalization tests were conducted no more than two times per week with the
following compounds: d-amphetamine (0, 0.03, 0.1, 0.3, and 1.0 mg/kg);
modafinil (0, 32, 64, 128, and 256 mg/kg); modafinil (32 mg/kg) in combination
with d-amphetamine (0, 0.03, 0.1, 0.3, 1.0 mg/kg); the selective D2 dopamine
agonist, PNU-91356A (0.01, 0.03, 0.1, and 0.3 mg/kg); morphine (2.5 and 5.0
mg/kg); ethanol (1.5 mg/kg). These compounds were tested in the order listed
above, and individual test doses of each compound were administered in a
counterbalanced order among the eight subjects in each training group. At each
dose level, half of the animals in each group were tested on a day following a
drug training session and the other half were tested on a day following a saline
training session. Test sessions were similar to discrimination training sessions
with the exception that no reinforcers were delivered and the animal was
immediately removed from the chamber following the completion of 20
consecutive responses on either lever or after 20 minutes had elapsed,
whichever occurred first. As with training sessions, incorrect responses reset the
response counter, but completion of a single FR ended a test session.
Data Analysis
The mean (± S.E.M.) number of sessions to meet the discrimination
criteria was calculated for each training group and a t-test was conducted to
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determine statistical significance in the sessions to criteria between groups.
Stimulus generalization was quantified as the percentage of total responses
emitted on the drug-appropriate lever. Complete stimulus generalization was
defined as a group mean of 80% or higher on any given dose. A group average
of 20 % to 80 % drug-lever selection was considered partial substitution for a
particular test dose. Response rate was expressed as responses per second and
calculated by dividing the total number of responses on either lever by the
number of seconds to complete a test session. Means (± S.E.M.) for these
dependent variables were calculated for each test dose and dose-response
curves were plotted from these data for each training group. For test compounds
producing dose-dependent increases in drug lever selection, separate one-way
repeated measures analysis of variance (ANOVA) tests were conducted to
assess the main effect of dose on percent drug-lever responses and response
rate. For animals that did not emit at least 20 responses during a test session,
that animal’s percent drug-lever selection data were excluded from graphs and
statistical analyses, but response rate was included. A nonlinear regression was
conducted on the d-amphetamine dose-response curves to estimate the median
effective dose (ED50) with and without the addition of 32 mg/kg modafinil.
Statistical analyses were conducted with SPSS (SPSS Statistics, Chicago, IL,
USA) and Prism GraphPad (GraphPad, San Diego, CA, USA).
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Results
Discrimination Acquisition
Stimulus control was readily established by both AMPH training doses,
although acquisition occurred more rapidly in the animals trained with 1.0 mg/kg
d-amphetamine (1.0 AMPH) compared to those trained with 0.3 mg/kg damphetamine (0.3 AMPH). All eight animals in the 1.0 AMPH group met the
discrimination criteria within 16 (± 0 S.E.M.) discrimination training sessions,
whereas the 0.3 AMPH group met these criteria within an average of 30 (± 2.8
S.E.M.) sessions (range: 22-46). A t-test on the number of sessions to meet
criteria was statistically significant between training groups [t (14) = 4.92, p <
0.01].
Determination of d-amphetamine Dose-response Curves
Dose-response curves for d-amphetamine in both the 0.3 AMPH and 1.0
AMPH training groups are depicted in Figure 8. The top graphs show the mean
(± S.E.M.) percentage of d-amphetamine-lever responses and the bottom graphs
depict mean (± S.E.M.) response rate. A one-way repeated measures ANOVA
on the percentage of drug-lever responses showed significant dose effects in the
1.0 AMPH group [F (4, 28) = 18.06, p < 0.001] and Bonferroni post-hoc tests
indicated that both 0.3 and 1.0 mg/kg produced significantly greater AMPH-lever
responses than saline in this group (p < 0.001). Response rates following
d-amphetamine were fairly stable across doses in the 1.0 AMPH group. A oneway repeated measures ANOVA on response rate was not significant for this
group.
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A one-way repeated measures ANOVA showed significant dose effects on
percent drug-lever selection in the 0.3 AMPH group [F (4, 24) = 7.63, p < 0.001].
Bonferonni post-hoc tests were statistically significant between saline and 0.3
mg/kg (p < 0.01) and between saline and 1.0 mg/kg (p < 0.05) d-amphetamine in
the 0.3 AMPH training group. A dose-dependent decrease in response rate was
observed with d-amphetamine in the 0.3 AMPH group and this effect was
statistically significantly [F (4, 28) = 6.49, p < 0.01], with significant Bonferroni
post-hoc tests between 1.0 mg/kg d-amphetamine and saline (p < 0.05).
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Modafinil Substitution Tests
Figure 9 depicts the results of stimulus generalization tests with modafinil
in both the 0.3 AMPH and 1.0 AMPH training groups. In both training groups,
modafinil produced a dose-dependent increase in d-amphetamine-lever
responses, with slightly higher group means following 32, 64, and 128 mg/kg
modafinil in the 0.3 AMPH group. However, a slightly higher percentage of druglever selection was observed following 256 mg/kg modafinil in the 1.0 AMPH
group (78%) compared to the 0.3 AMPH group (66%). Five of the eight animals
in the 0.3 AMPH group and six of the eight animals in the 1.0 AMPH group
exhibited complete stimulus generalization following the highest dose of
modafinil.
A repeated measures one-way ANOVA revealed a significant effect of
modafinil dose on percentage of drug-lever responses in the 1.0 AMPH group [F
(4, 28) = 5.92, p < 0.01]. Bonferroni post-hoc tests were significant between the
256 mg/kg dose and vehicle (p < 0.001). Modafinil had little effect on response
rate in the 1.0 AMPH group. A one-way repeated measures ANOVA on percent
drug-lever selection was also significant in 0.3 AMPH group [F (4, 28) = 3.01, p <
0.05]. Bonferroni post-hoc tests were significant between the 256 mg/kg dose
and vehicle for this group (p < 0.05). A one-way ANOVA on response rate in the
0.3 AMPH group was significant [F (4, 28) = 2.92, p < 0.05], although there were
no significant Bonferroni post-hoc tests.
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Substitution Tests with PNU-91356A, Ethanol, and Morphine
Results of stimulus generalization tests with PNU-91356A, ethanol, and
morphine are depicted in Table 1. As demonstration of a positive control, the D 2
dopamine agonist, PNU-91356A fully substituted in both training dose groups. In
contrast, ethanol and morphine showed no evidence of substitution in either
group, thus serving as valid negative controls. A one-way repeated measures
ANOVA on percentage of drug-lever responses following PNU-91356A was
significant in the 1.0 AMPH group [F (4, 16) = 18.61, p < 0.01]. Bonferroni posthoc tests showed significant differences between vehicle and the 0.3 mg/kg dose
in this group (p < 0.05). Response rate was significantly reduced by PNU-91356A
in this group [F (4, 20) = 23.82, p < 0.001], with significant post-hoc tests
between vehicle and both 0.1 and 0.3 mg/kg (p < 0.05).
A one-way repeated measures ANOVA on percentage of drug-lever
responses following PNU-91356A was also significant in the 0.3 AMPH group [F
(3, 18) = 29.33, p < 0.001] with significant Bonferroni post-hoc tests between
vehicle and 0.1 mg/kg (p < 0.001). Response suppression was severe in the 0.3
AMPH group following the administration of 0.3 mg/kg PNU-91356A; none of the
animals made 20 responses and the majority of them made fewer than five
responses following this dose. Furthermore, a one-way repeated measures
ANOVA on response rate in this group was statistically significant [F (4, 28) =
9.22,
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p < 0.05] with significant post-hoc tests between vehicle and 0.03, 0.1 and 0.3
mg/kg (p < 0.05).
Effects of Modafinil Pretreatment on d-amphetamine Discrimination
Figure 10 illustrates the results of substitution tests with 32 mg/kg
modafinil administered in combination with each dose of d-amphetamine (32
MOD+AMPH) in both the 1.0 AMPH training group (left panel) and the 0.3 AMPH
training group (right panel). For comparison, these graphs also include the damphetamine dose-response curves previously depicted in Figure 8. In animals
trained to discriminate 1.0 AMPH, pretreatment with 32 mg/kg modafinil did not
alter the d-amphetamine dose-response function. A nonlinear regression using a
sigmoidal dose-response function equation indicated a slight reduction of the
ED50 from 0.71 mg/kg (95% CI: 0.05-10.6) to 0.29 mg/kg (95% CI: 0.05-1.67). A
one-way repeated measures ANOVA on percentage of drug-lever responses
following the 32 MOD+AMPH dose combinations in the 1.0 AMPH group was
significant [F (4, 28) = 15.44, p < 0.001], with significant Bonferroni post-hoc tests
only between 32 MOD+SAL and 32 MOD+1.0 AMPH (p < 0.01). Although
modafinil pretreatment appeared to reduce the effects of d-amphetamine on
response rate, a one-way repeated measures ANOVA indicated no significant
rate suppressant effects of 32 MOD+AMPH.
Pretreatment with 32 mg/kg modafinil also shifted the d-amphetamine
dose-response curve slightly to the left in the 0.3 AMPH group, with a reduction
in the ED50 from 0.07 mg/kg (95% CI: 0.01-0.74) to 0.03 mg/kg (95% CI: 0.0013.7). A one-way repeated measures ANOVA on percentage of drug-lever
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responses following the 32 MOD+AMPH dose combinations in the 0.3 AMPH
group was statistically significant [F (4, 20) = 6.90, p < 0.001] and Bonferroni
post-hoc tests were significant between 32 MOD+SAL and both 32 MOD+0.3
AMPH (p < 0.01) and 32 MOD+1.0 AMPH (p < 0.01). Similar to the effects of damphetamine alone, 32 MOD+AMPH significantly reduced response rate in the
0.3 AMPH group [F (4, 28) = 3.35, p < 0.05] with significant Bonferroni post-hoc
tests between 32 MOD+SAL and 32 MOD+1.0 AMPH (p < 0.05).

Discussion
This study evaluated the wake-promoting agent, modafinil, for stimulus
generalization to the psychomotor stimulant, d-amphetamine, and assessed the
combined effects of these drugs in rats trained to discriminate either 0.3 or 1.0
mg/kg d-amphetamine. Consistent with a previous report by Dopheide et al.
(2007), the current findings indicate that modafinil produced only partial
substitution for d-amphetamine, while a low modafinil dose appeared to augment
the discrimination of low
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d-amphetamine doses. Dopheide et al. (2007) reported a four-fold reduction in
the d-amphetamine ED50 by pretreatment with 32 mg/kg modafinil, whereas the
current results showed approximately a two-fold decrease. This discrepancy
could be due to various methodological differences between the two studies,
such as different vehicles used for the modafinil mixture and different testing
procedures. Dopheide et al. (2007) delivered a single reinforcer following
completion of the FR requirement on either lever during test sessions, whereas
the current study conducted test sessions under extinction. Furthermore,
Dopheide et al. (2007) controlled for the pretreatment injection procedure by
administering vehicle prior to d-amphetamine test sessions, whereas the current
study did not utilize this control. This limitation precludes statistical analyses to
compare d-amphetamine dose response tests with and without modafinil
pretreatment. Nevertheless, the current findings indicate a visually evident trend
in the same direction as that reported by Dopheide et al. (2007), who
demonstrated that low doses of modafinil and d-amphetamine have additive
effects.
In parallel experiments, Dopheide et al. (2007) reported similar additive
effects of modafinil and cocaine, but only in rats trained to discriminate 1.6 mg/kg
and not those trained to discriminate 5 mg/kg cocaine. A slightly higher
percentage of cocaine-lever responding (60 and 70%) was observed in the group
trained to discriminate 1.6 mg/kg cocaine, but similar to the d-amphetamine
trained animals, none of the modafinil doses assessed substituted for either dose
of cocaine. Results of the current study are consistent with those of Dopheide et
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al. (2007) in that 32-128 mg/kg modafinil produced only partial substitution in rats
trained to discriminate either 0.3 or 1.0 mg/kg d-amphetamine-hemisulfate (s.c.).
Additionally, the present study found a higher modafinil dose (256 mg/kg) was
required to produce full substitution in a significant portion of the animals tested.
Although the group average did not exceed 80% drug lever selection, it is
noteworthy that the majority of animals, five in the 0.3 AMPH training group and
six in the 1.0 AMPH training group, exhibited full stimulus generalization to 256
mg/kg modafinil. A higher dose of modafinil may produce full substitution for
d-amphetamine. Indeed, Paterson et al. (2010) demonstrated full substitution
with 300 mg/kg modafinil (i.p.) in rats trained to discriminate 10 mg/kg cocaine.
A recent comprehensive review by Stolerman, Childs, Ford & Grant (2011)
summarizes several key principles derived from research on the role of training
dose in drug discrimination. Notably, higher training doses tend to produce
enhanced discrimination accuracy, whereas lower training doses tend to produce
lower ED50 values with the training drug and enhanced sensitivity in stimulus
generalization tests with other test compounds. Previous studies comparing
different d-amphetamine training doses generally support these conclusions
(Stolerman and D’Mello, 1981; Barrett and Steranka, 1983; Stadler, Caul &
Barrett, 2001). Results of the current study are partly consistent with these
general principles. The 0.3 AMPH group required nearly twice as many training
sessions to attain the criteria for stimulus control and the d-amphetamine ED50
was 10 times lower in this group compared to the 1.0 AMPH group. However, the
dose-response curves between the two training groups were not as robust as
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expected. Stimulus generalization to modafinil also varied only slightly between
the 0.3 AMPH and 1.0 AMPH training dose groups. Lower modafinil doses (32,
64, 128 mg/kg) produced only slightly higher d-amphetamine-lever selection in
the 0.3 AMPH group compared to the 1.0 AMPH group, and 256 mg/kg modafinil
actually produced a slightly greater mean percentage of drug-appropriate
responses in the 1.0 AMPH group. Minor differences in the modafinil doseresponse curves between the two training groups fail to support the principle that
a lower training dose yields greater sensitivity to other test compounds, it is worth
noting that the 0.3 AMPH group was somewhat more sensitive to the combined
effects of low modafinil and d-amphetamine doses compared to the 1.0 AMPH
group.
Although the drug discrimination paradigm does not directly assess abuse
liability, it is a useful model for assessing qualitative responses to drug
combinations and may provide a method for investigating the influence of prior
drug history on drug sensitivity. Regular use of low dose oral medications for
therapeutic purposes and the high dose use by injection or intranasal routes for
recreational purposes represent two distinct patterns and levels of
psychostimulant use by humans. While modafinil use at low doses for therapeutic
purposes presents a low risk for abuse and dependence, more frequent use of
high doses may pose a higher risk for dependence. Moreover, the concurrent
use of modafinil with other stimulants might pose a greater risk for abuse due to
additive effects. The drug discrimination results of Dopheide et al. (2007), and to
some extent the current findings indicate modafinil may have additive effects with
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other psychostimulants. Thus, an experiment was designed to more directly
investigate the combined effects of d-amphetamine and modafinil in the drug
discrimination paradigm by training animals to discriminate 256 mg/kg modafinil.
A secondary aim of this experiment was to elucidate the pharmacological
mechanism of action of modafinil utilizing an in vivo assay.
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CHAPTER V
EXPERIMENT 4: DUAL DOPAMINERGICE MECHANISMS MEDIATE
MODAFINIL’S DISCRIMINATIVE STIMULUS EFFECTS
Overview
Given that higher doses of modafinil partially or fully substitute in animals
trained to discriminate cocaine (Loland et al., 2012; Newman et al., 2010;
Paterson et al., 2010; Gold & Balster, 1996) or d-amphetmaine (Dopheide et al.,
2007), it is possible that cocaine or d-amphetamine will produce stimulus
generalization in animals trained to discriminate modafinil. No published study to
date has investigated modafinil as the trained discriminative stimulus in a drug
discrimination paradigm. In order to directly assess modafinil’s pharmacological
mechanism of action, animals were trained to discriminate 256 mg/kg modafinil
and substitution tests were conducted with d-amphetamine, modafinil plus damphetamine, and several other dopaminergic agonists or antagonists.

Methods
Subjects
Eight male Sprague-Dawley rats (Charles River, Portage, MI) were singly
housed in polycarbonate cages lined with corncob bedding in a colony room at
Western Michigan University maintained on a 12:12 light/dark cycle with lights on
from 7:00 a.m. to 7:00 p.m. Water was provided ad libitum and food was
restricted in order to maintain animals’ weights at 85% - 90% of their free-feeding
weights. A standard 14 grams of rat chow was received on all training days and
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standard 18 grams was received on all test days and days when data was not
collected. All procedures were reviewed and approved by the Western Michigan
University Institutional Animal Care and Use Committee.
Apparatus
Training and testing sessions were conducted in eight standard operant
conditioning chambers (ENV-001; MED Associates Inc., Georgia, VT, USA),
housed within sound- and light- attenuating shells. Each chamber was equipped
with three removable levers located on the front panel, a food pellet dispenser, a
28-V house light, and a fan. Forty-five mg food pellets served as the reinforcers
(Bioserv; Frenchtown, NJ). Experimental events were programmed and
controlled using Version IV Med-PC software (MED Associates Inc., St. Albans,
VT, USA).
Drugs
Modafinil was synthesized in the laboratory of Dr. Thomas Prisinzano
using previously described methods (Prisinzano, et al., 2004). Suspensions were
prepared fresh each day in a 5% arabic gum solution (Sigma Aldrich, St. Louis,
MO) and administered by oral gavage (i.g.) in a volume of 10 ml/kg 30 minutes
prior to test sessions. d-Amphetamine-hemisulfate (Sigma-Aldrich, St. Louis,
MO) and PNU-91356A (Pharmacia & Upjohn, Inc., Kalamazoo MI) were
dissolved in 0.9% NaCl and administered i.p. 10 minutes prior to test sessions.
GBR 12909 bismethanesulfonate monohydrate was prepared in the Chemical
Biology Research Branch (National Institute on Drug Abuse and the National
Institute on Alcohol Abuse and Alcoholism) and was dissolved in sterile water
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and administered i.p. 30 minutes prior to test sessions. (-)-Nicotine hydrogen
tartrate (Sigma-Aldrich, St. Louis, MO) was dissolved in 0.9% NaCl and
administered i.p.15 minutes before testing. Schering 39166 (Shering-Plough
Corporation, Bloomfield, NJ) was dissolved in 0.9% NaCl and administered i.p.
10 minute prior to modafinil (256 mg/kg) administration. Haloperidol (SigmaAldrich, St. Louis, MO) was dissolved in 0.9% NaCl and administered i.p. 30
minute prior to modafinil (256 mg/kg) administration.
Procedures
Preliminary Training. Preliminary training consisted of two one-hour
sessions with no levers present and food pellets were delivered according to a
fixed-time 60 second schedule to acclimate the rats to the sound and location of
food pellet delivery. All subsequent training sessions lasted 20 minutes and were
conducted once per day, five or six days a week. Lever pressing was initially
reinforced on the center lever via an autoshaping program under a continuous
reinforcement schedule for one 20 min session. Center lever press training
continued for seven additional sessions during which the FR schedule was
programmed to increment by a designated amount (e.g., 1, 2, or 5) after the
delivery of five reinforcers at a particular FR value. Once all animals were reliably
lever pressing at FR 20, errorless training commenced with only the left or right
lever present.
Drug (D) or vehicle (V) injections were administered via oral gavage (i.g.)
30 minutes prior to errorless training sessions. Drug injections consisted of 256
mg/kg modafinil and vehicle injections consisted of a 5 % arabic gum solution.
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For four rats, errorless training sessions with only the right lever present followed
drug injections and errorless training sessions with only the left lever present
followed saline injections. Conditions were reversed for the remaining four rats.
All rats were exposed to six errorless training sessions in the following order: V,
V, D, D, V, D. Responses were initially reinforced under a FR 1 schedule and the
FR value was gradually incremented within each training session and across the
six errorless training sessions with each stimulus condition. Within each session,
the FR was programmed to increment by a designated amount (e.g., 1, 2, or 5)
after the delivery of five reinforcers at a particular FR value. Across training
sessions, the starting FR value was determined for each individual rat by the last
FR value obtained in the previous session. All rats were responding on a FR 20
schedule by the last errorless training session with each stimulus condition.
Discrimination Training Procedures. Immediately following the completion
of errorless training, discrimination training commenced with both levers present.
The first session with both levers present was designated as day one for
determining the number of training sessions required for each animal to meet the
discrimination criteria. Similar to errorless training sessions, discrimination
training under each stimulus condition began on a FR 1 schedule and the FR
was increased gradually until the final FR 20 was reached under each stimulus
condition. Once animals were reliably responding on an FR 20 schedule under
both stimulus conditions, the FR 20 remained in effect for subsequent training
and the remainder of the study.
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Drug and saline training sessions were administered in a pseudo-random
order, with the limitation that no animal received more than two consecutive drug
or two consecutive saline sessions throughout the study. Consistent with
errorless training conditions, half of the rats were reinforced for right lever
responses following modafinil injections and for left lever responses following
vehicle injections; conditions were reversed for the remaining rats. The chambers
and levers were wiped clean with isopropyl alcohol after each session to reduce
the influence of olfactory stimuli on lever selection (Extance and Goudie, 1981).
The criteria for stimulus discrimination required animals to emit a minimum of
80% correct lever responses prior to the delivery of the first reinforcer and for the
remainder of the training session for at least 8 of 10 consecutive discrimination
training sessions.
Testing Procedures. Stimulus generalization tests commenced when each
subject met the criteria described above. In between test sessions, animals were
administered no less than one drug training session and one vehicle training
session and were required to exhibit 80% response accuracy on the first FR as
well as during the total session under both conditions to continue testing. If an
animal did not meet these criteria, training sessions continued until criterion was
met with each stimulus condition on two consecutive days. Generalization tests
were conducted no more than two times per week with the following compounds:
modafinil (0, 32, 64, 128, 256, and 384 mg/kg); d-amphetamine (0, 0.03, 0.1, 0.3,
and 1.0 mg/kg); d-amphetamine (0, 1.0, or 0.1 mg/kg) in combination with
modafinil (0, 32, 64, 128, 256, and 384 mg/kg); the selective D2 dopamine
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agonist, PNU-91356A (0.01, 0.03, 0.1, and 0.3 mg/kg); the DAT inhibitor, GBR
12909 (0, 5, 10, 20, and 30 mg/kg); nicotine (0, 0.1, 0.2, 0.4, and 0.8 mg/kg); and
cocaine (0, 2.5, 5, and 10 mg/kg). Antagonist tests were conducted with the
selective D1 DA antagonist, Schering 39166 (0, 0.03, 0.1, 0.3 mg/kg, i.p.) and the
D2 DA antagonist, haloperidol (0, 0.125, 0.25, 0.5 mg/kg, i.p.). Individual test
doses of each compound were administered in a counterbalanced order among
the eight subjects. At each dose level, half of the animals were tested on a day
following a drug training session and the other half were tested on a day
following a vehicle training session. Test sessions were similar to discrimination
training sessions with the exception that no reinforcers were delivered and the
animal was immediately removed from the chamber following the completion of
20 consecutive responses on either lever or after 20 minutes had elapsed,
whichever occurred first. As with training sessions, incorrect responses reset the
response counter, but completion of a single FR ended a test session.
Data Analysis
Stimulus generalization was quantified as the percentage of total
responses emitted on the drug-appropriate lever. Complete stimulus
generalization was defined as a group mean of 80% or higher on any given dose.
A group average of 20 % to 80 % drug-lever selection was considered partial
substitution for a particular test dose. Response rate was expressed as
responses per second and calculated by dividing the total number of responses
on either lever by the number of seconds to complete a test session. Means (±
S.E.M.) for these dependent variables were calculated for each test dose and
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dose-response curves were plotted from these data for each training group. For
test compounds producing dose-dependent increases in drug lever selection,
separate one-way repeated measures analysis of variance (ANOVA) tests were
conducted to assess the main effect of dose on percent drug-lever responses
and response rate. For animals that did not emit at least 20 responses during a
test session, that animal’s percent drug-lever selection data were excluded from
graphs and statistical analyses, but response rate was included. Statistical
analyses were performed using Prism GraphPad (GraphPad, San Diego, CA,
USA).

Results
Discrimination Acquisition
Modafinil established stimulus control in all eight animals within an
average of 36 (± 2.4) discrimination training sessions (range: 23-43). At session
numbers 180 and 195, two animals stopped discriminating during the drug
stimulus condition though reliably met criteria during the vehicle stimulus
condition. As a result, these animals were returned to errorless training sessions
with 256 mg/kg modafinil and vehicle stimulus conditions for 24 sessions. After
both levers were presented again, each of these animals still did not meet
discrimination criteria during the drug condition. For one animal, the dose was
then increased to 384 mg/kg and 10 errorless training sessions were run. This rat
met the discrimination criteria after 20 additional discrimination training sessions.
The other animal was not put on errorless training when the dose was increased
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to 384 mg/kg and failed to reach discrimination criteria after 20 sessions. As a
result these two animals are excluded from statistical analyses for all data
obtained after the training dose was increased. The data from these animals is
only included in the statistical analyses for modafinil and d-amphetamine doseresponse curves.
Determination of Modafinil dose-response Curves
Figure 11 displays the agonist substitution tests with PNU-91356A,
nicotine, d-amphetamine, GBR 12909, cocaine, and modafinil. Percent druglever selection is shown in the upper panel and response rate is displayed in the
bottom panel. Modafinil produced a dose-dependent increase in percent
modafinil-lever responses with full substitution at the training dose. A repeated
measures one-way ANOVA revealed a significant effect of modafinil dose on
percentage of drug-lever responses [F (6, 42) = 5.29, p < 0.001]. Tukey post-hoc
tests were significant between the 256 mg/kg dose and both the vehicle condition
(p < 0.001) and the 16 mg/kg dose (p < 0.05). There were also significant
differences between 384 mg/kg and the vehicle condition (p < 0.01). A one-way
repeated measures ANOVA on response rate after modafinil administration was
not statistically significant.
Substitution Tests with d-amphetamine
Half of the animals were severely disrupted when tested with 3.0 mg/kg
and did not meet response criteria to be included in the analyses. As such, this
dose was eliminated from the statistical analysis but is included in the visual
representation of the data (see Figure 11). d-Amphetamine produced dose-
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dependent increases in percent modafinil-lever responses with significant partial
substitution at the highest dose tested that also markedly decreased response
rate. A one-way repeated measures ANOVA excluding the 3 mg/kg dose (due to
low N) revealed a significant effect of d-amphetamine dose on percentage of
drug-lever responses [F (4, 28) = 3.76, p < 0.05]. Tukey post-hoc tests were
significant between 1.0 mg/kg and the vehicle control dose (p < 0.05) and
between 0.03 mg/kg and 1.0 mg/kg d-amphetamine (p < 0.05). A one-way
repeated measures ANOVA on response rate for the five doses in the
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d-amphetamine generalization gradient was statistically significant [F (4, 28) =
4.92, p < 0.001] with significant Tukey post-hoc tests between 1.0 mg/kg and
three conditions: vehicle (p < 0.05), 0.03 mg/kg (p < 0.05), 0.1 mg/kg (p < 0.01).
Substitution Tests with PNU-91356A
Most of the animals were severely disrupted on the highest dose tested
(0.3 mg/kg) and didn’t emit enough responses to be included in the statistical
analysis. As such, this dose was excluded from the statistical analysis of percent
modafinil-lever responding, but was included in the statistical analysis of
response rate and the graphic depiction of the dose-response curve (see Figure
11). Substantial partial substitution for modafinil was observed with 0.1 mg/kg
PNU-91356A while no substitution was observed with the other doses. A oneway repeated measures ANOVA on percent modafinil-lever selection revealed a
significant main effect of PNU-91356A dose [F (3, 9) = 5.12, p < 0.05]. Tukey
post-hoc tests were significant between the 0.1 mg/kg dose and vehicle (p <
0.05). Response rate decreased dose-dependently and the one way repeated
measures ANOVA was significant [F (4, 12) = 6.51, p < 0.001]. Significant Tukey
post-hoc tests revealed a difference between the vehicle condition and both the
0.1 mg/kg (p < 0.01) and 0.3 mg/kg dose (p < 0.01).
Substitution Tests with GBR12909
GBR12909 administration produced dose-dependent increases in drugappropriate responding, with full substitution at the highest dose (30 mg/kg). The
dose response curve for this test compound is depicted in Figure 11. A one-way
repeated measures ANOVA on percent modafinil-lever responses revealed a
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significant effect of GBR12909 dose [F (4, 20) = 3.47, p < 0.05]. Tukey post-hoc
tests were significant between the highest test dose (30 mg/kg) and the vehicle
(p < 0.05) test condition. This compound also produced dose-dependent
decreases in response rate. A one-way repeated measures ANOVA on response
rate for the GBR12909 generalization tests was statistically significant [F (4, 20)
= 6.15, p < 0.01] with significant Tukey post-hoc tests between the highest dose
tested (30 mg/kg) and three conditions: vehicle (p < 0.001), 5 mg/kg (p < 0.05),
and 20 mg/kg (p < 0.05).
Substitution Tests with (-)-Nicotine Hydrogen Tartrate
Only partial generalization was produced by nicotine administration even
at the highest dose (see Figure 11). A repeated measures one-way ANOVA
revealed a significant effect of nicotine dose on percentage of drug-lever
responses [F (4, 20) = 8.11, p < 0.001]. Tukey post-hoc tests were significant
between the vehicle condition and both 0.4 mg/kg (p < 0.01) and 0.8 mg/kg (p <
0.01) conditions. There was also a significant difference between 0.2 mg/kg and
0.4 mg/kg (p < 0.05). Visual analysis of response rate data after nicotine
administration suggests a dose-dependent decrease in responding, however a
one-way repeated measures ANOVA on response rate for the nicotine found no
statistically significant differences among doses.
Substitution Tests with Cocaine
The cocaine dose-response curve represents only four animals that have
completed all test doses to date. Full substitution for modafinil was observed with
2.5 mg/kg and 5 mg/kg cocaine while partial substitution was observed at 1.25
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mg/kg and 10 mg/kg cocaine. Moreover, a one-way repeated measures ANOVA
on percent modafinil-lever selection revealed a significant main effect of cocaine
dose [F (4, 12) = 6.78, p < 0.01]. Tukey post-hoc tests were significant between
the all test doses and the vehicle (p < 0.05) condition. Response rate decreased
dose-dependently, but the one way repeated measures ANOVA was not
significant.
Substitution Tests with Modafinil in Combination with d-amphetamine
(0.1 and 1.0 mg/kg)
Figure 12 represents the results of 1.0 mg/kg or 0.1 mg/kg d-amphetamine
+ modafinil (16-384 mg/kg) compared to modafinil alone with percent drug-lever
selection presented on the right and response rate shown on the left. Only five
animals completed the dose-response curve for modafinil in combination with 0.1
mg/kg d-amphetamine. A two way repeated measures ANOVA on the difference
among the three curves (modafinil alone, modafinil + 1.0 mg/kg d-amphetamine,
and 0.1 mg/kg d-amphetamine + modafinil) revealed significant main effects of
pretreatment [F(2, 12) = 10.51, p < 0.01] and dose [F(6, 54) = 4.55, p < 0.001],
but no significant interaction. A two factor repeated measures ANOVA on
response rate found a significant effect of pretreatment [F(2, 12) = 8.09, p <
0.01].
Another two way repeated measures ANOVA utilizing data from seven
animals was conducted to compare the results of modafinil substitution tests and
the substitution tests with 1.0 mg/kg d-amphetamine + modafinil. There were
significant main effects of dose [F(6, 72) = 5.39, p < 0.001] and pretreatment
[F(1, 12) = 40.08, p < 0.001] and a significant interaction effect [F(6, 72) = 3.53, p
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< 0.01]. Tukey post-hoc tests indicate statistically significant differences in
percent drug-lever responses following the 1.0 d-Amphetamine + vehicle (p <
0.01) and the 1.0 d-Amphetamine + 16 mg/kg modafinil (p < 0.01) dose
combinations. A two factor repeated measures ANOVA comparing response rate
following modafinil and 1.0 mg/kg d-amphetamine + modafinil administration
revealed a main effect of pretreatment [F(1, 12) = 27.97, p < 0.001] and no other
significant effects.
Antagonist Tests
Figure 13 displays the results of Sch 39166 and haloperidol administered in
combination with modafinil. Percent modafinil-lever selection is presented in the
right panel and response rate is displayed in the left panel. Dose-dependent
decreases in percent modafinil-lever selection and response rate are evident for
both compounds. A repeated measures one-way ANOVA revealed a significant
effect of Sch 39166, dose on percentage of drug-lever responses [F (3, 15) =
18.29, p < 0.001].
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Tukey post-hoc tests were significant between the vehicle condition and both 0.1
mg/kg (p < 0.001) and 0.3 mg/kg (p < 0.001) test doses and between the 0.03
mg/kg test dose and both 0.1 mg/kg (p < 0.001) and 0.3 mg/kg (p < 0.01).
Response rate was analyzed with a repeated measures one-way ANOVA and
revealed no significant effect of Sch 39166 dose.
A repeated measures one-way ANOVA revealed a significant effect of
haloperidol, dose on percentage of drug-lever responses [F (3, 9) = 4.99, p <
0.05]. Tukey post-hoc tests were significant between the vehicle condition and
the highest dose tested (0.5 mg/kg) (p < 0.01). Response rate was analyzed with
a one-way repeated measures ANOVA, which revealed a significant main effect
of dose [F (3, 12) = 9.63, p < 0.01]. Tukey post-hoc tests were significant
between the highest dose (0.5 mg/kg) and all other dose conditions (p < 0.01).
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Discussion
This experiment investigated the pharmacological mechanism of action of
modafinil using an in vivo behavioral assay (drug discrimination) and evaluated
the combined effects of d-amphetamine and modafinil for potentiation in animals
trained to discriminate 256 mg/kg modafinil. This is the first study to evaluate the
pharmacological mechanism of modafinil by utilizing the compound as the
training compound in a drug discrimination paradigm. Moreover, it is the first to
demonstrate that 256 mg/kg modafinil can function as a discriminative stimulus in
rodents. Substitution tests with d-amphetamine produced nearly complete
substitution for modafinil at a dose that markedly suppressed responding. This
finding is consistent with previous reports (Dopheide et al., 2007) that modafinil
partially substitutes in rats trained to discriminate a low dose of d-amphetamine.
Results showing partial substitution with the D2 agonist, PNU-91356A, full
substitution with the DAT inhibitors, GBR 12909 and cocaine in addition to
complete blockade with the D1 antagonist, Sch 39166 and the D2 antagonist,
haloperidol suggest dual dopaminergic mechanisms contribute to the
discriminative stimulus functions of modafinil. These results confirm those of
previous studies using in vitro techniques that report inhibition of the DAT and
both D1 and D2 DA receptors are involved in modafinil’s neuropharmacological
actions (Loland et al., 2012; Anderson et al., 2009; Nguyen et al., 2011;
Korotkova et al., 2007) and behavioral effects (Wisor et al., 2001).
The unexpected finding that the cholinergic agonist, nicotine, produced
partial substitution for modafinil is of particular interest. Although nicotine is not a
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direct DA agonist, it does increase dopamine efflux in the nucleus accumbens
and dopamine antagonists have been shown to block its discriminative stimulus
effects (Di Chiara, 2000). The results from this study suggest modafinil and
nicotine may have similar stimulus properties. Given that it took researchers
several years to determine the environmental events necessary to establish
nicotine self-administration or CPP in nonhumans (Le Full & Goldberg, 2006),
further research may be required to determine whether variables such as age,
motivation, drug history, or schedule or reinforcement (Le Full & Goldberg, 2006)
could affect abuse liability screening results with modafinil. Further research
investigating these procedural variables and extent to which dopaminergic
actions contribute to similar motor and discriminative stimulus functions of
nicotine and modafinil warrant further investigation.
The results of the combination dose-response curves demonstrated that a
dose of d-amphethamine (1.0 mg/kg) that initially produced only partial
substitution for modafinil produced complete substitution when combined with a
range of modafinil doses. However, for the present analysis there was not a
proper control condition to compare the combination curves. A modafinil +
d-amphetamine vehicle dose-response curve must be determined for a proper
comparison. Generalization tests with this control condition are currently in
progress. In addition to this limitation, there were also no negative control tests
conducted to verify discrimination to a specific class of drugs versus a simple
psychoactive effect. With the exception of nicotine, drugs tested for substitution
or blockage were dopaminergic agonists and antagonists, therefore no
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conclusions can be made regarding the possible role of other neurotransmitter
systems in modafinil’s discriminative stimulus effects. Future investigations
should focus on the evaluation of other neurotransmitter systems, in particular
the NE and 5-HT systems. Although, cocaine and d-amphetamine are well
known to act upon the DAT system, both also produce mechanistic actions
involving these neurotransmitter systems (Glennon & Young, 2011). DAT and 5HT transporter inhibitors readily substitute for cocaine and enhance the
discriminative stimulus effects of low doses of cocaine in rats trained to
discriminate low dose cocaine (Kleven & Koek, 1998). These authors also argue
that interactions with the NE are sufficient, but not necessary in the discriminative
stimulus effects of cocaine. Evaluation of the discriminative stimulus effects of damphetamine however revealed substitution with NE transporter inhibitors
(Kamien & Woolverton, 1988) suggesting this is a primary mechanism involved in
maintaining the discriminative stimulus effects of d-amphetamine. Given that the
NE system appears to be important for the locomotor activating effects of
modafinil (Hermant et al., 1991), further investigation of shared discriminative
stimulus function of modafinil and other psychostimulants is warranted.
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CHAPTER VI
GENERAL DISCUSSION
These studies evaluated the abuse liability of low to moderate doses of
the alertness-promoting drug, modafinil, in three preclinical behavioral assays.
Results of the behavioral sensitization and CPP experiments confirm previous
reports that modafinil has low abuse liability. Specifically, a brief history of
repeated d-amphetamine exposure did not sensitize rats to the locomotor effects
of modafinil (Experiment 1), nor did concurrent administration of low doses of
modafinil and d-amphetamine exert additive effects on CPP (Experiment 2).
However, results of the drug discrimination experiments (Experiments 3 and 4)
may be interpreted to suggest the opposite. Evidence of partial substitution with
modafinil in animals trained to discriminate either a low or moderately high dose
of d-amphetamine in addition to partial or full substitution with dopamine agonists
in animals trained to discriminate modafinil indicate dopaminergic mechanisms
may be critically important to maintaining modafinil’s discriminative stimulus
effects. Many abused substances increase DA levels in the mesolimbic pathway
that includes the ventral tegmental area, nucleus accumbens, and other
corticolimbic regions. As such, these areas are implicated in the abuse liability of
many psychoactive drugs. Psychostimulants, in particular, exert effects through
the DA system and increase concentrations in this reward pathway (Spanagel &
Weiss, 1999). Modafinil likely influences activities within this system and
therefore may have potential for abuse.
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In a recent review of preclinical, human laboratory, and clinical research,
Herin, Rush, & Grabowski, (2010) summarized the rationale for agonist-like
pharmacotherapy for stimulant dependence; medications with properties similar
to the abused drug, but exhibiting a lower abuse liability may modify
neurochemistry and stabilize behavior, and subsequently reduce drug use.
Evidence demonstrated by the experiments in this study seem to support this
claim. Furthermore, recent in vitro research demonstrating modafinil-induced
DAT binding had a longer duration of action and was less efficacious than
cocaine supports the use of modafinil as an agonist replacement therapy for
cocaine dependence (Loland et al., 2012).
The results of investigations by Dopheide et al. (2007) and Experiment 3
of the current research indicate modafinil can augment the discrimination of low
dose psychostimulants. Similarly, the results of Experiment 4 demonstrate that damphetamine can augment the discrimination of modafinil. Some authors have
argued that drug discrimination in nonhuman models can be used to predict the
potential therapeutic effectiveness of medications for the treatment of stimulant
dependence (Li, Campbell & Katz, 2006). Specifically, Li et al. (2006) suggest
that a drug that produces a leftward shift in a stimulant dose effect curve in drug
discrimination might be a viable option for agonist replacement therapy. In
consideration of this suggestion, the current experimental findings as well as
those reported by Dopheide et al. (2007) support further evaluation of modafinil
as an agonist replacement therapy for psychostimulant dependence.
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Results of studies utilizing animal models of drug reinstatement following
self-administration also seem to support modafinil as a treatment for
psychostimulant dependence. Following extinction of methamphetamine selfadministration, modafinil did not reinstate methamphetamine seeking and
actually blocked methamphetamine-primed and cue-primed reinstatement
(Reichel & See, 2010). In a follow up investigation, Reichel and See (2012)
reported that chronic modafinil treatment attenuated cue-induced and
methamphetamine-primed reinstatement, and even reduced methamphetamineseeking behaviors following discontinuation of treatment. They also reported only
a high dose of modafinil (300 mg/kg) reduced methamphetamine intake during
maintenance of self-administration.
Although the results of some preclinical studies provide a rationale for
modafinil as a pharmacotherapy for psychostimulant dependence, substantial
evidence is currently lacking regarding its clinical efficacy in this regard. Indeed,
recent clinical investigations of modafinil as an agonist replacement therapy have
yielded mixed results. In a double-blind placebo controlled trial, Shearer et al.
(2009) compared modafinil (200 mg/day) to placebo in participants seeking
treatment for methamphetamine dependence. Treatment retention and
medication adherence were equivalent between groups, though modafinil was
reported to reduce methamphetamine use only in participants who received
modafinil and remained medication compliant over the 10-week treatment period.
Based on these findings, Shearer et al. (2009) promoted the continued
assessment of modafinil for the treatment of methamphetamine dependence in
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large multi-site clinical trials. Although preliminary clinical trials showed increased
cocaine abstinence in modafinil-treated patients compared to placebo-treated
patients over an eight week period (Dackis et al., 2005), a more recent study
failed to support these findings. In a double-blind, placebo-controlled randomized
clinical trial with cocaine-dependent participants. Schmitz et al. (2012) compared
the therapeutic effectiveness of 400 mg modafinil to 60 mg d-amphetamine and
the combination of 200 mg modafinil and 30 mg d-amphetamine. Retention rates
did not differ among treatment groups and the participants administered the
medication combination actually showed a trend for increased cocaine use over
the course of the 16-week study compared to groups administered only
d-amphetamine or placebo. Based on these preliminary findings, Schmitz et al.
(2012) advised against continued assessment of this dual-agonist medication
combination in a larger population.
Few studies have examined the combined effects of modafinil and other
psychostimulants for additive effects. One possible interpretation of the findings
from Experiment 3 and 4 is that modafinil’s subjective effects may be enhanced
when used in combination with d-amphetamine, which could increase its abuse
liability. The findings of Schmitz et al. (2012) regarding increased relapse to
cocaine use in patients administered combination therapy with modafinil and
amphetamine is consistent with this interpretation. Thus, despite modafinil’s
apparent low abuse liability, the combined behavioral effects of modafinil and
psychostimulants should be evaluated more carefully before continuing clinical
assessments with modafinil for psychostimulant dependence. In particular,
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additional preclinical investigations utilizing other methodologies to examine
modafinil across a wide range of doses and in combination with other stimulants,
such as behavioral sensitization paradigms or drug self-administration may be of
interest.
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